US5800815A
(en)
*
|
1903-05-05 |
1998-09-01 |
Cytel Corporation |
Antibodies to P-selectin and their uses
|
US5851526A
(en)
*
|
1985-04-19 |
1998-12-22 |
Ludwig Institute For Cancer Research |
Methods of treating colon cancer utilizing tumor-specific antibodies
|
US5449760A
(en)
*
|
1987-12-31 |
1995-09-12 |
Tanox Biosystems, Inc. |
Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US7247453B1
(en)
*
|
1988-12-30 |
2007-07-24 |
Oklahoma Medical Research Foundation |
Calcium binding recombinant antibody against protein C
|
DE3900534A1
(de)
*
|
1989-01-10 |
1990-07-12 |
Boehringer Mannheim Gmbh |
Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
|
US6750325B1
(en)
|
1989-12-21 |
2004-06-15 |
Celltech R&D Limited |
CD3 specific recombinant antibody
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
GR1001050B
(el)
*
|
1990-01-09 |
1993-04-28 |
Protein Design Labs Inc |
Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων.
|
HUT60768A
(en)
|
1990-03-16 |
1992-10-28 |
Sandoz Ag |
Process for producing cd25 fixing molecules
|
GB9020282D0
(en)
*
|
1990-09-17 |
1990-10-31 |
Gorman Scott D |
Altered antibodies and their preparation
|
US5858725A
(en)
*
|
1990-10-10 |
1999-01-12 |
Glaxo Wellcome Inc. |
Preparation of chimaeric antibodies using the recombinant PCR strategy
|
US5994510A
(en)
*
|
1990-12-21 |
1999-11-30 |
Celltech Therapeutics Limited |
Recombinant antibodies specific for TNFα
|
CZ282603B6
(cs)
*
|
1991-03-06 |
1997-08-13 |
Merck Patent Gesellschaft Mit Beschränkter Haftun G |
Humanizované a chimerické monoklonální protilátky
|
IL101147A
(en)
*
|
1991-03-07 |
2004-06-20 |
Gen Hospital Corp |
Change of direction of cellular immunity by chimera receptors
|
DK0578774T3
(da)
*
|
1991-04-05 |
1999-04-26 |
Univ Washington |
Monoklonale antistoffer mod stamcellefaktor-receptorer
|
AU668349B2
(en)
*
|
1991-04-25 |
1996-05-02 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human interleukin 6 receptor
|
EP0519596B1
(en)
*
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
CA2103059C
(en)
*
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
GB9115010D0
(en)
*
|
1991-07-11 |
1991-08-28 |
Wellcome Found |
Antibody
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
US5756096A
(en)
*
|
1991-07-25 |
1998-05-26 |
Idec Pharmaceuticals Corporation |
Recombinant antibodies for human therapy
|
US6136310A
(en)
*
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
EP0596032B2
(en)
*
|
1991-07-25 |
2004-04-07 |
Idec Pharmaceuticals Corporation |
Induction of cytotoxic t-lymphocyte responses
|
IE922437A1
(en)
*
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
US5709860A
(en)
*
|
1991-07-25 |
1998-01-20 |
Idec Pharmaceuticals Corporation |
Induction of cytotoxic T-lymphocyte responses
|
US6685939B2
(en)
|
1991-08-14 |
2004-02-03 |
Genentech, Inc. |
Method of preventing the onset of allergic disorders
|
US6329509B1
(en)
|
1991-08-14 |
2001-12-11 |
Genentech, Inc. |
Anti-IgE antibodies
|
DK0528767T3
(da)
*
|
1991-08-21 |
2000-04-17 |
Novartis Ag |
antistofderivater
|
GB9120467D0
(en)
*
|
1991-09-26 |
1991-11-06 |
Celltech Ltd |
Anti-hmfg antibodies and process for their production
|
JP3024311B2
(ja)
*
|
1991-10-03 |
2000-03-21 |
味の素株式会社 |
Il−2受容体重鎖に結合するポリペプチド
|
US5474771A
(en)
|
1991-11-15 |
1995-12-12 |
The Trustees Of Columbia University In The City Of New York |
Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
|
US7070777B1
(en)
|
1991-11-15 |
2006-07-04 |
The Trustees Of Columbia University In The City Of New York |
Method for inhibiting inflammation with an antibody that binds the 5C8 protein
|
US5817310A
(en)
*
|
1991-12-02 |
1998-10-06 |
Cor Therapeutics, Inc. |
Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
|
JPH05244982A
(ja)
*
|
1991-12-06 |
1993-09-24 |
Sumitomo Chem Co Ltd |
擬人化b−b10
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
JP4157160B2
(ja)
*
|
1991-12-13 |
2008-09-24 |
ゾーマ テクノロジー リミテッド |
改変抗体可変領域の調製のための方法
|
US5777085A
(en)
*
|
1991-12-20 |
1998-07-07 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with GPIIB/IIIA
|
US5824307A
(en)
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
CA2129663C
(en)
*
|
1992-02-06 |
2005-07-05 |
James S. Huston |
Biosynthetic binding protein for cancer marker
|
GB9203459D0
(en)
*
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
US5714350A
(en)
*
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5387676A
(en)
*
|
1992-03-11 |
1995-02-07 |
Ciba Corning Diagnostics Corp. |
MN gene and protein
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
US6129914A
(en)
*
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
US6033667A
(en)
*
|
1992-05-05 |
2000-03-07 |
Cytel Corporation |
Method for detecting the presence of P-selectin
|
US5874082A
(en)
*
|
1992-07-09 |
1999-02-23 |
Chiron Corporation |
Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
|
US5397703A
(en)
*
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
US5639641A
(en)
*
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US6066718A
(en)
*
|
1992-09-25 |
2000-05-23 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
US5958708A
(en)
*
|
1992-09-25 |
1999-09-28 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
GB9223377D0
(en)
*
|
1992-11-04 |
1992-12-23 |
Medarex Inc |
Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
|
DE669986T1
(de)
*
|
1992-11-13 |
1996-10-10 |
Idec Pharma Corp |
Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
|
NZ258392A
(en)
|
1992-11-13 |
1997-09-22 |
Idec Pharma Corp |
Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
|
US5736137A
(en)
*
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US7744877B2
(en)
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
US5648267A
(en)
*
|
1992-11-13 |
1997-07-15 |
Idec Pharmaceuticals Corporation |
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
|
US5804187A
(en)
*
|
1992-11-16 |
1998-09-08 |
Cancer Research Fund Of Contra Costa |
Modified antibodies with human milk fat globule specificity
|
DE69419721T2
(de)
|
1993-01-12 |
2000-04-27 |
Biogen Inc |
Rekombinante anti-vla4 antikörpermoleküle
|
US5951983A
(en)
*
|
1993-03-05 |
1999-09-14 |
Universite Catholique De Louvain |
Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
|
US5817311A
(en)
*
|
1993-03-05 |
1998-10-06 |
Universite Catholique De Louvain |
Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
|
US5730979A
(en)
*
|
1993-03-05 |
1998-03-24 |
Universite Catholique Delouvain |
LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
|
EP0804235A4
(en)
*
|
1993-05-04 |
2001-09-19 |
Aeres Biomedical Ltd |
ANTIBODIES AGAINST SELECTIN P AND USES THEREOF
|
ATE335072T1
(de)
*
|
1993-05-28 |
2006-08-15 |
Scripps Research Inst |
Methoden für inhibition der cd14-abhängigen zellaktivierung
|
ZA943778B
(en)
*
|
1993-05-31 |
1995-02-21 |
Chugai Seiyaku Kagushiki Kaish |
Reshaped human antibody to human interleukin-6
|
US6180377B1
(en)
*
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
US5914110A
(en)
*
|
1993-09-07 |
1999-06-22 |
Smithkline Beecham Corporation |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
US5928904A
(en)
*
|
1993-09-07 |
1999-07-27 |
Smithkline Beecham Corporation |
DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
KR100362340B1
(ko)
*
|
1993-09-07 |
2003-02-26 |
스미스클라인비이참피이엘시이 |
인터로이킨-4(il4)매개된질환의치료에유용한재조합il4항체
|
AU7949394A
(en)
|
1993-11-19 |
1995-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human medulloblastomatous cell
|
WO1995015181A1
(en)
*
|
1993-11-30 |
1995-06-08 |
Protein Design Labs, Inc. |
Reperfusion therapy using antibodies to l-selectin
|
GB9325182D0
(en)
*
|
1993-12-08 |
1994-02-09 |
T Cell Sciences Inc |
Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
|
US5840299A
(en)
*
|
1994-01-25 |
1998-11-24 |
Athena Neurosciences, Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
US7435802B2
(en)
|
1994-01-25 |
2008-10-14 |
Elan Pharaceuticals, Inc. |
Humanized anti-VLA4 immunoglobulins
|
EP0804237B8
(en)
*
|
1994-01-25 |
2006-11-08 |
Elan Pharmaceuticals, Inc. |
Humanized antibodies against leukocyte adhesion molecule vla-4
|
NZ282849A
(en)
|
1994-03-29 |
1998-05-27 |
Celltech Therapeutics Ltd |
Antibodies against e-selectin; whole antibodies of neutral isotype, being variants of natural antibodies altered in the fc region
|
US5635597A
(en)
*
|
1994-05-27 |
1997-06-03 |
Affymax Technologies, N.V. |
Peptides that bind IL-2 receptors
|
US5622701A
(en)
|
1994-06-14 |
1997-04-22 |
Protein Design Labs, Inc. |
Cross-reacting monoclonal antibodies specific for E- and P-selectin
|
GB9412230D0
(en)
|
1994-06-17 |
1994-08-10 |
Celltech Ltd |
Interleukin-5 specific recombiant antibodies
|
USRE39548E1
(en)
*
|
1994-06-17 |
2007-04-03 |
Celltech R&D Limited |
Interleukin-5 specific recombinant antibodies
|
US6048972A
(en)
*
|
1994-07-13 |
2000-04-11 |
Chugai Pharmaceutical Co., Ltd. |
Recombinant materials for producing humanized anti-IL-8 antibodies
|
DE4425115A1
(de)
*
|
1994-07-15 |
1996-01-18 |
Boehringer Mannheim Gmbh |
Verfahren zur Modifizierung der Stabilität von Antikörpern
|
EP0696455A1
(en)
*
|
1994-08-11 |
1996-02-14 |
Cellena (Cell Engineering) A.G. |
Transferrin compositions to alleviate the side effects of cytotoxic drugs
|
US8771694B2
(en)
*
|
1994-08-12 |
2014-07-08 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
|
US5707621A
(en)
*
|
1994-08-31 |
1998-01-13 |
Chugai Pharmaceutical Co., Ltd. |
Supression of nephritis-induced protein excretion by anti-IL-8
|
US6309636B1
(en)
*
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
US5693323A
(en)
*
|
1994-12-23 |
1997-12-02 |
Smithkline Beecham Corporation |
Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
|
US5811524A
(en)
*
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
US6113898A
(en)
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7175847B1
(en)
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US7153508B2
(en)
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
AU6171196A
(en)
*
|
1995-06-07 |
1996-12-30 |
Sloan-Kettering Institute For Cancer Research |
Therapeutic uses of ta99
|
US6440418B1
(en)
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
US6001358A
(en)
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
GB9600660D0
(en)
|
1996-01-12 |
1996-03-13 |
Ciba Geigy Ag |
Protein
|
WO1997033617A1
(en)
*
|
1996-03-13 |
1997-09-18 |
Protein Design Labs, Inc. |
Fas ligand fusion proteins and their uses
|
US5882644A
(en)
*
|
1996-03-22 |
1999-03-16 |
Protein Design Labs, Inc. |
Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
|
US6713305B1
(en)
|
1996-04-29 |
2004-03-30 |
Novartis Ag |
Metastasis-associated antigen and antibodies thereto
|
EP1378525A3
(en)
|
1996-06-07 |
2004-01-14 |
Neorx Corporation |
Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
|
US6534311B2
(en)
|
1996-07-24 |
2003-03-18 |
Novartis Ag |
Drosophila melanogaster p70S6 kinase
|
US6833255B1
(en)
|
1996-07-24 |
2004-12-21 |
Novartis, Ag |
Drosophila melanogaster p70 S6 kinase
|
US7147851B1
(en)
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
EP1642908A2
(en)
*
|
1996-09-02 |
2006-04-05 |
Okumura, Ko |
Apoptosis-induced site from fas ligand
|
US6013256A
(en)
*
|
1996-09-24 |
2000-01-11 |
Protein Design Labs, Inc. |
Method of preventing acute rejection following solid organ transplantation
|
EP0962467A4
(en)
|
1996-09-26 |
2002-10-30 |
Chugai Pharmaceutical Co Ltd |
ANTIBODIES AGAINST HUMAN PARATHORMON RELATED PEPTIDES
|
UA76934C2
(en)
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
US7883872B2
(en)
|
1996-10-10 |
2011-02-08 |
Dyadic International (Usa), Inc. |
Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
|
US7910096B2
(en)
|
1996-11-15 |
2011-03-22 |
Trustees Of Tufts College |
Human neutralizing antibodies against hemolytic uremic syndrome
|
US20020160005A1
(en)
|
1996-11-15 |
2002-10-31 |
Trustees Of Tufts College |
Human neutralizing antibodies against hemolytic urmec syndrome
|
EP2371962A3
(en)
|
1996-12-23 |
2011-12-21 |
Immunex Corporation |
Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
|
US6262238B1
(en)
*
|
1997-01-14 |
2001-07-17 |
Roche Diagnostic, Gmbh |
Process for modifying the stability of antibodies
|
US6596850B1
(en)
|
1998-01-30 |
2003-07-22 |
Ixsys, Incorporated |
Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
|
US6590079B2
(en)
|
1997-01-30 |
2003-07-08 |
Ixsys, Incorporated |
Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
|
US20030109680A1
(en)
|
2001-11-21 |
2003-06-12 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US5986065A
(en)
|
1997-03-10 |
1999-11-16 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US7749498B2
(en)
|
1997-03-10 |
2010-07-06 |
Genentech, Inc. |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US20060235209A9
(en)
|
1997-03-10 |
2006-10-19 |
Jin-An Jiao |
Use of anti-tissue factor antibodies for treating thromboses
|
IL123756A0
(en)
*
|
1997-03-21 |
1998-10-30 |
Sankyo Co |
Humanized anti-human FAS antibody
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
ES2273415T3
(es)
|
1997-04-07 |
2007-05-01 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
ATE361099T1
(de)
*
|
1997-05-15 |
2007-05-15 |
Chugai Pharmaceutical Co Ltd |
Heilmittel für kachexie
|
JP2002512624A
(ja)
|
1997-05-21 |
2002-04-23 |
バイオベーション リミテッド |
非免疫原性タンパク質の製造方法
|
ES2221212T5
(es)
|
1997-10-02 |
2008-12-01 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Metodos para la modulacion de la neovascularizacion y/o el crecimiento de arterias colaterales y/o de otras arterias a partir de conexiones arteriolares preexistentes.
|
US7052873B2
(en)
*
|
1997-10-03 |
2006-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Natural human antibody
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
EP1745799B1
(en)
|
1998-03-04 |
2015-09-02 |
The Trustees of The University of Pennsylvania |
Compositions and methods of treating tumors
|
IL138801A0
(en)
|
1998-04-03 |
2001-10-31 |
Chugai Pharmaceutical Co Ltd |
Humanized antibody against human tissue factor and process for the preparation thereof
|
EA004107B1
(ru)
|
1998-08-11 |
2003-12-25 |
Айдек Фармацевтикалс Корпорэйшн |
Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
|
JP4689781B2
(ja)
*
|
1998-09-03 |
2011-05-25 |
独立行政法人科学技術振興機構 |
アミノ酸輸送蛋白及びその遺伝子
|
PT1113810E
(pt)
|
1998-09-14 |
2009-03-10 |
Univ Texas |
Processos de tratamento de mieloma múltiplo e reabsorção óssea induzida por mieloma utilizando antagonistas da ligação do receptor de integrina
|
KR100618495B1
(ko)
|
1998-10-06 |
2006-08-31 |
마크 아론 에말파브 |
섬유상의 진균성 숙주 영역에서의 형질전환 시스템:크리소스포륨속에서
|
EP1939215A1
(en)
|
1998-10-22 |
2008-07-02 |
The University of Montana |
Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
|
WO2000027428A1
(en)
|
1998-11-09 |
2000-05-18 |
Idec Pharmaceuticals Corporation |
Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
|
GB9825632D0
(en)
|
1998-11-23 |
1999-01-13 |
Novartis Ag |
Organic compounds
|
US20030035798A1
(en)
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
JP2002538167A
(ja)
|
1999-03-03 |
2002-11-12 |
バイオジェン インコーポレイテッド |
脂質の代謝および貯蔵を調節する方法
|
GB9906380D0
(en)
*
|
1999-03-19 |
1999-05-12 |
Melvin William T |
Monoclonal antibodies specific for cypibi
|
CN1191860C
(zh)
|
1999-04-22 |
2005-03-09 |
比奥根公司 |
利用整联蛋白α4亚单位的拮抗剂治疗纤维变性的方法
|
IT1306704B1
(it)
*
|
1999-05-26 |
2001-10-02 |
Sirs Societa Italiana Per La R |
Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
|
TR200103432T2
(tr)
|
1999-06-01 |
2002-10-21 |
Biogen, Inc. |
Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
US6531580B1
(en)
|
1999-06-24 |
2003-03-11 |
Ixsys, Inc. |
Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
|
TWI255718B
(en)
|
1999-07-02 |
2006-06-01 |
Chugai Pharmaceutical Co Ltd |
Ameliorative agent for low vasopressin concentration
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
CA2386197A1
(en)
*
|
1999-09-30 |
2001-04-05 |
Kyowa Hakko Kogyo Co., Ltd. |
Complementarity determining region-grafted antibody against ganglioside gd3 and derivative of antibody against ganglioside gd3
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
CA2394431C
(en)
|
1999-12-16 |
2015-06-30 |
Jane Relton |
Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
|
ATE474854T1
(de)
|
2000-01-27 |
2010-08-15 |
Medimmune Llc |
Rsv neutralisierende antikörper mit sehr hohen affinität
|
EP1255844B1
(en)
*
|
2000-02-03 |
2007-09-19 |
Millennium Pharmaceuticals, Inc. |
Humanized anti-ccr2 antibodies and methods of use therefor
|
AU3495301A
(en)
|
2000-02-11 |
2001-08-20 |
Biogen Inc |
Heterologous polypeptide of the tnf family
|
DK1481992T3
(en)
|
2000-02-24 |
2017-01-30 |
Washington Univ St Louis |
Humanized antibodies which sequester amyloid beta peptide
|
CA2401652A1
(en)
|
2000-03-01 |
2001-09-07 |
Medimmune, Inc. |
High potency recombinant antibodies and method for producing them
|
JP2003527439A
(ja)
|
2000-03-17 |
2003-09-16 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
抗cd18抗体と抗ccr2抗体の混合物を用いる狭窄および再狭窄を抑制する方法
|
US20010046496A1
(en)
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
EP1283057B2
(en)
|
2000-04-28 |
2012-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Cell proliferation inhibitors
|
WO2001084149A2
(en)
|
2000-04-29 |
2001-11-08 |
University Of Iowa Research Foundation |
Diagnostics and therapeutics for macular degeneration-related disorders
|
US7476383B2
(en)
|
2000-05-02 |
2009-01-13 |
The Uab Research Foundation |
Antibody selective for DR4 and uses thereof
|
US7279160B2
(en)
|
2000-05-02 |
2007-10-09 |
The Uab Research Foundation |
Combinations of DR5 antibodies and other therapeutic agents
|
TWI318983B
(en)
|
2000-05-02 |
2010-01-01 |
Uab Research Foundation |
An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
|
GB0013810D0
(en)
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
ES2357051T3
(es)
|
2000-10-02 |
2011-04-15 |
Novartis Vaccines And Diagnostics, Inc. |
Anticuerpos humanos anti-cd40.
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
ES2314067T3
(es)
|
2001-04-06 |
2009-03-16 |
University Of Bristol |
Uso de moleculas de enlace cd 25 en pacientes resistentes a los esteroides.
|
CN1561345B
(zh)
|
2001-04-13 |
2011-09-14 |
比奥根艾迪克Ma公司 |
抗vla-1的抗体
|
YU91403A
(sh)
*
|
2001-05-18 |
2006-05-25 |
Boehringer Ingelheim International Gmbh. |
Antitela specifična za cd44v6
|
US6972324B2
(en)
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
US7541443B2
(en)
*
|
2001-06-14 |
2009-06-02 |
Tolerrx, Inc. |
Anti-CD4 antibodies
|
DE60233509D1
(de)
|
2001-06-20 |
2009-10-08 |
Fibron Ltd |
Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
|
US20030013081A1
(en)
|
2001-06-26 |
2003-01-16 |
Olson William C. |
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
|
JP4675512B2
(ja)
*
|
2001-07-10 |
2011-04-27 |
三井化学株式会社 |
熱殺菌方法
|
US20030138440A1
(en)
|
2001-07-19 |
2003-07-24 |
Fang Fang |
Multimeric proteins and methods of making and using same
|
DE60226036T9
(de)
|
2001-08-03 |
2016-09-29 |
Medical & Biological Laboratories Co., Ltd. |
ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
|
ES2391905T3
(es)
|
2001-08-17 |
2012-11-30 |
Washington University |
Método de ensayo para la enfermedad de alzheimer
|
WO2003035887A1
(en)
|
2001-09-20 |
2003-05-01 |
Immunex Corporation |
Selection of cells expressing heteromeric polypeptides
|
RU2305111C2
(ru)
|
2001-09-25 |
2007-08-27 |
Джуридикэл Фаундейшн Дзе Чемо-Серо-Терапьютик Рисерч Инститьют |
Рекомбинантное антитело против остеопонтина и его применение
|
GB0124317D0
(en)
|
2001-10-10 |
2001-11-28 |
Celltech R&D Ltd |
Biological products
|
US7151164B2
(en)
*
|
2002-02-14 |
2006-12-19 |
Immunomedics, Inc. |
Anti-CD20 antibodies and fusion proteins thereof and methods of use
|
US20030190705A1
(en)
*
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
CA2466592A1
(en)
*
|
2001-11-12 |
2003-05-22 |
Koen Hellendoorn |
Modified anti-tnf alpha antibody
|
MXPA04004876A
(es)
|
2001-11-21 |
2004-07-30 |
Univ Pennsylvania |
Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso.
|
EP1944043A1
(en)
|
2001-11-21 |
2008-07-16 |
The Trustees of the University of Pennsylvania |
Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
|
EP1461300B1
(en)
|
2001-11-30 |
2011-07-27 |
Biogen Idec MA Inc. |
Antibodies against monocyte chemotactic proteins
|
JP4723810B2
(ja)
*
|
2001-12-03 |
2011-07-13 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
ハイブリッド抗体
|
US7393648B2
(en)
|
2001-12-03 |
2008-07-01 |
Alexion Pharmaceuticals, Inc. |
Hybrid antibodies
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
RU2322454C2
(ru)
*
|
2002-02-22 |
2008-04-20 |
Проджиникс Фармасьютикалз, Инк. |
Антитело против ccr5
|
SI2336184T1
(sl)
|
2002-02-25 |
2015-04-30 |
Biogen Idec Ma Inc. |
Dajanje sredstev za zdravljenje vnetij
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
CA2478833C
(en)
|
2002-03-13 |
2015-11-10 |
Biogen, Inc. |
Anti-.alpha.v.beta.6 antibodies
|
PT1495056E
(pt)
|
2002-03-20 |
2011-03-29 |
Ucb Pharma Sa |
Métodos de análise
|
WO2003080675A2
(en)
*
|
2002-03-22 |
2003-10-02 |
Amrad Operations Pty Ltd |
MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13Rα1)
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
WO2003097798A2
(en)
|
2002-05-14 |
2003-11-27 |
Martek Biosciences Corporation |
Carotene synthase gene and uses therefor
|
WO2003099226A2
(en)
|
2002-05-28 |
2003-12-04 |
Celltech R & D Limited |
Antibody peg positional isomers, compositions comprising same, and use thereof
|
AU2003232456B2
(en)
*
|
2002-05-30 |
2009-06-04 |
Macrogenics, Inc. |
CD16A binding proteins and use for the treatment of immune disorders
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
GB0213745D0
(en)
|
2002-06-14 |
2002-07-24 |
Univ Edinburgh |
Enzyme
|
DE60230071D1
(de)
|
2002-06-14 |
2009-01-08 |
Monier Tadros |
Methode für die herstellung von protamin
|
WO2004002500A1
(en)
|
2002-06-28 |
2004-01-08 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
|
WO2010011999A2
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of California |
Methods and compositions for eliciting an amyloid-selective immune response
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
GB0228832D0
(en)
|
2002-12-10 |
2003-01-15 |
Novartis Ag |
Organic compound
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
EP1578397B1
(en)
|
2002-11-15 |
2012-12-26 |
Genmab A/S |
Human monoclonal antibodies against cd25
|
CA2537263C
(en)
|
2002-11-27 |
2017-05-30 |
Minerva Biotechnologies Corporation |
Techniques and compositions for the diagnosis and treatment of cancer (muc1)
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
WO2004065417A2
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
CA2514125A1
(en)
|
2003-01-24 |
2004-08-12 |
Elan Pharmaceuticals, Inc. |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
EP1460088A1
(en)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
US7321065B2
(en)
|
2003-04-18 |
2008-01-22 |
The Regents Of The University Of California |
Thyronamine derivatives and analogs and methods of use thereof
|
NZ542866A
(en)
|
2003-04-23 |
2009-07-31 |
Medarex Inc |
Compositions and methods for the therapy of inflammatory bowel disease
|
ES2368737T3
(es)
*
|
2003-04-23 |
2011-11-21 |
Medarex, Inc. |
Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
CA2526900C
(en)
|
2003-05-19 |
2015-11-24 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in lewy body disease
|
AU2004253868B2
(en)
|
2003-06-13 |
2011-06-16 |
Biogen Ma Inc. |
Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
|
US8153410B2
(en)
|
2003-07-07 |
2012-04-10 |
Fox Chase Cancer Center |
Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
|
US20060162014A1
(en)
|
2003-07-07 |
2006-07-20 |
Jaffe Eileen K |
Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
|
SI2784084T2
(sl)
|
2003-07-08 |
2024-02-29 |
Novartis Pharma Ag |
Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
|
CN103880955A
(zh)
|
2003-07-18 |
2014-06-25 |
安姆根有限公司 |
肝细胞生长因子的特异性结合物
|
US7834155B2
(en)
|
2003-07-21 |
2010-11-16 |
Immunogen Inc. |
CA6 antigen-specific cytotoxic conjugate and methods of using the same
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
GB0321997D0
(en)
|
2003-09-19 |
2003-10-22 |
Novartis Ag |
Organic compound
|
AU2004287722A1
(en)
*
|
2003-11-11 |
2005-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized anti-CD47 antibody
|
JP2007514413A
(ja)
|
2003-11-12 |
2007-06-07 |
プロジェニクス・ファーマスーティカルズ・インコーポレイテッド |
C型肝炎ウイルス糖タンパク質をコードする新規配列
|
ES2324538T3
(es)
|
2003-12-05 |
2009-08-10 |
Multimmune Gmbh |
Anticuerpos anti-hsp terapeuticos y de diagnostico.
|
CA2548813A1
(en)
|
2003-12-08 |
2005-06-23 |
Morphotek, Inc. |
Antibodies that specifically bind pms2
|
WO2005058244A2
(en)
|
2003-12-15 |
2005-06-30 |
Alexion Pharmaceuticals, Inc. |
Novel anti-dc-sign antibodies
|
ITRM20030601A1
(it)
*
|
2003-12-24 |
2005-06-25 |
Lay Line Genomics Spa |
Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
|
PT2311873T
(pt)
|
2004-01-07 |
2018-11-20 |
Novartis Vaccines & Diagnostics Inc |
Anticorpo monoclonal específico para m-csf e respetivos usos
|
EP1712566A4
(en)
|
2004-01-19 |
2007-09-12 |
Medical & Biol Lab Co Ltd |
INFLAMMATORY CYTOKINE INHIBITOR
|
JP2007521811A
(ja)
|
2004-01-30 |
2007-08-09 |
ダナ ファーバー キャンサー インスティテュート |
放射線又は遺伝毒性物質曝露の測定及び定量方法
|
CA2561531C
(en)
|
2004-02-10 |
2017-05-02 |
The Regents Of The University Of Colorado |
Inhibition of factor b, the alternative complement pathway and methods related thereto
|
JP4805848B2
(ja)
|
2004-02-12 |
2011-11-02 |
モルフォテック、インク. |
腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体
|
TWI359026B
(en)
|
2004-02-12 |
2012-03-01 |
Sankyo Co |
Pharmaceutical composition for the osteoclast rela
|
EP1717250A4
(en)
|
2004-02-20 |
2008-10-01 |
Immuno Biological Lab Co Ltd |
MONOCLONAL ANTIBODY AND ITS USE
|
JP4960859B2
(ja)
|
2004-03-12 |
2012-06-27 |
バスジーン セラピューティクス,インコーポレイテッド |
血管形成及び腫瘍成長を阻害するためのポリペプチド化合物
|
AU2005227313A1
(en)
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through V gene manipulation
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
RS52918B
(en)
|
2004-04-02 |
2014-02-28 |
The Regents Of The University Of California |
PROCEDURES AND MIXTURES FOR TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH ALFA V BETA 5 INTEGRINE
|
CA2568201C
(en)
|
2004-05-24 |
2013-07-30 |
Universitat Zu Koln |
Identification of ergothioneine transporter and therapeutic uses thereof
|
EP1602926A1
(en)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Novel means and methods for the treatment of hearing loss and phantom hearing
|
AU2005258077C1
(en)
|
2004-06-21 |
2012-10-25 |
E. R. Squibb & Sons, L.L.C. |
Interferon alpha receptor 1 antibodies and their uses
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
RS20070027A
(en)
|
2004-07-26 |
2008-11-28 |
Biogen Idec Ma Inc., |
Anti-cd154 antibodies
|
GB0417487D0
(en)
|
2004-08-05 |
2004-09-08 |
Novartis Ag |
Organic compound
|
EA013752B1
(ru)
|
2004-08-09 |
2010-06-30 |
Элан Фармасьютикалз, Инк. |
Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
|
CA2478458A1
(en)
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
FI20041204A0
(fi)
|
2004-09-16 |
2004-09-16 |
Riikka Lund |
Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
|
JP2008520186A
(ja)
|
2004-10-01 |
2008-06-19 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
哺乳類eag1イオンチャネルタンパク質に対する新規の抗体
|
AU2005295038B2
(en)
|
2004-10-06 |
2012-05-17 |
Mayo Foundation For Medical Education And Research |
B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
|
US7928205B2
(en)
|
2004-10-22 |
2011-04-19 |
Amgen Inc. |
Methods for refolding of recombinant antibodies
|
EP2465872A3
(en)
|
2004-10-25 |
2012-12-19 |
Merck Sharp & Dohme Corporation |
Anti-ADDL antibodies and uses thereof
|
EP2808033A1
(en)
|
2004-11-19 |
2014-12-03 |
Biogen Idec MA Inc. |
Treatment for multiple sclerosis
|
JP2008523815A
(ja)
|
2004-12-15 |
2008-07-10 |
エラン ファーマ インターナショナル リミテッド |
認知の改善における使用のためのヒト化アミロイドβ抗体
|
DE602006003695D1
(de)
|
2005-01-05 |
2009-01-02 |
F Star Biotech Forsch & Entw |
Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften
|
EP2682126B1
(en)
|
2005-01-27 |
2016-11-23 |
Children's Hospital & Research Center at Oakland |
GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
|
NZ595305A
(en)
|
2005-02-14 |
2013-06-28 |
Univ Iowa Res Found |
Methods and reagents for treatment and diagnosis of age-related macular degeneration
|
DK2529619T3
(en)
|
2005-02-17 |
2016-01-11 |
Biogen Ma Inc |
Treatment of neurological disorders
|
JP4942644B2
(ja)
|
2005-02-28 |
2012-05-30 |
株式会社抗体研究所 |
抗IgSF4抗体及びその利用
|
AU2006218489B2
(en)
|
2005-03-02 |
2011-02-24 |
Biogen Ma Inc. |
KIM-1 antibodies for treatment of Th2-mediated conditions
|
EP2322560B1
(en)
|
2005-03-10 |
2013-09-04 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
EP1863531A1
(en)
|
2005-03-19 |
2007-12-12 |
Medical Research Council |
Improvements in or relating to treatment and prevention of viral infections
|
PT1866339E
(pt)
|
2005-03-25 |
2013-09-03 |
Gitr Inc |
Moléculas de ligação a gitr e suas utilizações
|
ES2720288T3
(es)
|
2005-03-30 |
2019-07-19 |
Minerva Biotechnologies Corp |
Proliferación de células que expresan MUC1
|
EP2527365A3
(en)
|
2005-03-30 |
2013-02-20 |
Minerva Biotechnologies Corporation |
Proliferation of MUC1 expressing cells
|
CN101189023B
(zh)
|
2005-03-31 |
2013-01-30 |
通用医疗公司 |
监测和调制hgf/hgfr活性
|
LT3264094T
(lt)
|
2005-04-04 |
2021-04-12 |
Biogen Ma Inc. |
Imuninio atsako į terapijos agentą įvertinimo būdai
|
JP2008538700A
(ja)
|
2005-04-22 |
2008-11-06 |
モルフォテック、インク. |
免疫エフェクター活性を有するエンドシアリン細胞に内部移行する抗体
|
EP1879922A2
(en)
|
2005-04-22 |
2008-01-23 |
Morphotek, Inc. |
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
|
WO2006117910A1
(ja)
|
2005-04-28 |
2006-11-09 |
Mochida Pharmaceutical Co., Ltd. |
抗血小板膜糖蛋白質ⅵモノクローナル抗体
|
EP1885396A2
(en)
|
2005-05-04 |
2008-02-13 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against cd55 and cd59 and uses thereof
|
SG10201809390QA
(en)
|
2005-05-10 |
2018-11-29 |
Incyte Holdings Corp |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
US7964200B2
(en)
|
2005-05-18 |
2011-06-21 |
Children's Hospital & Research Center At Oakland |
Methods and compositions for immunizing against Chlamydia infection
|
CA2607663C
(en)
|
2005-05-19 |
2014-08-12 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
CN103505728A
(zh)
|
2005-05-26 |
2014-01-15 |
科罗拉多大学评议会法人机构 |
用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
|
LT2460831T
(lt)
|
2005-05-27 |
2016-12-12 |
Biogen Ma Inc. |
Tweak rišantys antikūnai
|
WO2006138429A2
(en)
|
2005-06-16 |
2006-12-28 |
The Feinstein Institute For Medical Research |
Antibodies against hmgb1 and fragments thereof
|
ES2547463T3
(es)
|
2005-06-17 |
2015-10-06 |
Merck Sharp & Dohme Corp. |
Moléculas de unión a ILT3 y usos de las mismas
|
SI2314623T1
(sl)
*
|
2005-06-21 |
2012-11-30 |
Xoma Technology Ltd |
IL beta vezavna protitelesa in njihovi fragmenti
|
CN102875681A
(zh)
|
2005-07-08 |
2013-01-16 |
拜奥根Idec马萨诸塞公司 |
抗-αvβ6抗体及其用途
|
MX2008000984A
(es)
|
2005-07-22 |
2008-04-04 |
Progenics Pharm Inc |
Metodos para reducir la carga viral en pacientes infectados con vih-1.
|
FR2888850B1
(fr)
|
2005-07-22 |
2013-01-11 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
EP2311876A3
(en)
|
2005-07-28 |
2011-04-27 |
Novartis AG |
M-CSF-specific monoclonal antibody and uses thereof
|
WO2007030560A2
(en)
|
2005-09-08 |
2007-03-15 |
Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine |
Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
|
CA2623197A1
(en)
|
2005-09-22 |
2007-03-29 |
Prosci Incorporated |
Glycosylated polypeptides produced in yeast mutants and methods of use thereof
|
CA2627309A1
(en)
|
2005-10-28 |
2007-05-03 |
Meiji Seika Kaisha, Ltd. |
Pseudomonas aeruginosa outer membrane protein pa5158
|
WO2007051077A2
(en)
|
2005-10-28 |
2007-05-03 |
The Regents Of The University Of California |
Methods and compounds for lymphoma cell detection and isolation
|
BRPI0618085A2
(pt)
|
2005-11-01 |
2011-08-16 |
Abbott Biotech Ltd |
processos e kits para diagnóstico de espondilite ancilosante usando biomarcadores
|
WO2007062037A2
(en)
|
2005-11-21 |
2007-05-31 |
Laboratoires Serono Sa |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
KR101667623B1
(ko)
†
|
2005-11-30 |
2016-10-19 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
TWI428143B
(zh)
|
2006-01-18 |
2014-03-01 |
Gen Hospital Corp |
增加淋巴功能之方法
|
JP2009531295A
(ja)
|
2006-02-22 |
2009-09-03 |
ユニバーシティ オブ チューリッヒ |
自己免疫疾患又は脱髄疾患を処置するための方法
|
EP2377887A1
(en)
|
2006-03-10 |
2011-10-19 |
Zymogenetics Inc |
Antibodies that bind both IL-17A and IL-17F and methods of using the same
|
EP2522727A1
(en)
|
2006-03-23 |
2012-11-14 |
Tohoku University |
Highly functional bispecific antibody
|
WO2007114340A1
(ja)
|
2006-03-30 |
2007-10-11 |
Meiji Seika Kaisha, Ltd. |
緑膿菌の外膜タンパク質pa0427
|
CA2911000A1
(en)
|
2006-04-05 |
2007-10-18 |
Min W. Wan |
Antibody purification
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
EP2666479A3
(en)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
EP2666472A3
(en)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of psoriatic arthritis
|
DK2034830T3
(da)
|
2006-05-25 |
2014-10-27 |
Biogen Idec Inc |
Anti-vla-1-antistof til behandling af slagtilfælde
|
BRPI0711229A2
(pt)
|
2006-05-31 |
2013-01-08 |
Astellas Pharma Inc |
anticorpo humanizado da osteopontina anti-humana, polinucleotÍdeo, vetor de expressço, cÉlula hospedeita, mÉtodo para produzir um anticorpo humanizado de osteopontina anti-humana, fÁrmaco terapÊutico, mÉtodo para prevenir ou tratar doenÇa autoimune e uso do anticorpo humanizado de oesteopontina anti-humana
|
CA2653628C
(en)
|
2006-06-01 |
2015-07-14 |
Elan Pharmaceuticals, Inc. |
Neuroactive fragments of app
|
CA2655504A1
(en)
|
2006-06-15 |
2007-12-21 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
EP2041180B8
(en)
|
2006-06-19 |
2014-03-05 |
Liquidating Trust |
Ilt3 binding molecules and uses therefor
|
JP5535623B2
(ja)
|
2006-06-30 |
2014-07-02 |
アッヴィ バイオテクノロジー リミテッド |
自動注射装置
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
JP2009542196A
(ja)
|
2006-07-07 |
2009-12-03 |
インターセル アーゲー |
小型の化膿連鎖球菌抗原およびそれらの使用
|
KR20090027241A
(ko)
|
2006-07-10 |
2009-03-16 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Smad4-결핍 암의 성장을 억제하기 위한 조성물 및 방법
|
EP2078732B1
(en)
|
2006-07-10 |
2015-09-16 |
Fujita Health University |
Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
|
CN101626783A
(zh)
|
2006-08-04 |
2010-01-13 |
诺华有限公司 |
Ephb3-特异性抗体和其应用
|
EP2056709A4
(en)
|
2006-08-11 |
2013-05-01 |
Univ New Jersey Med |
DOUBLE-SENSITIZER WITH LUMINESCENCE COMPOUNDS, CONJUGATES AND USE
|
EP2059535B1
(en)
|
2006-08-18 |
2013-11-06 |
Novartis AG |
Prlr-specific antibody and uses thereof
|
BRPI0716762A2
(pt)
|
2006-09-13 |
2013-09-24 |
Abbott Lab |
melhorias da cultura celular
|
EP2500416A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
WO2008032833A1
(fr)
|
2006-09-14 |
2008-03-20 |
Medical & Biological Laboratories Co., Ltd. |
Anticorps présentant une activité adcc accrue et son procédé de production
|
FR2906533B1
(fr)
|
2006-09-28 |
2013-02-22 |
Pf Medicament |
Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
|
AU2007315211B2
(en)
|
2006-11-03 |
2013-01-17 |
U3 Pharma Gmbh |
FGFR4 antibodies
|
KR101512203B1
(ko)
|
2006-11-10 |
2015-04-15 |
가부시키가이샤 리부텍쿠 |
in vivo 에서 항종양 활성을 갖는 항인간 Dlk-1 항체
|
KR20090078353A
(ko)
|
2006-11-17 |
2009-07-17 |
노파르티스 아게 |
Lingo 결합 분자 및 그의 제약학적 용도
|
EP1923069A1
(en)
|
2006-11-20 |
2008-05-21 |
Intercell AG |
Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
|
US8288110B2
(en)
|
2006-12-04 |
2012-10-16 |
Perkinelmer Health Sciences, Inc. |
Biomarkers for detecting cancer
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
WO2008073914A2
(en)
|
2006-12-10 |
2008-06-19 |
Dyadic International Inc. |
Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
|
WO2008083169A2
(en)
|
2006-12-26 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
EP2586458B1
(en)
|
2006-12-27 |
2016-08-24 |
The Johns Hopkins University |
Compositions and methods for treating inflammation and auto-immune diseases
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
WO2008083331A2
(en)
|
2006-12-29 |
2008-07-10 |
The Regents Of The University Of Colorado |
Diagnostic and therapeutic target for autoimmune diseases and uses thereof
|
SG177954A1
(en)
|
2007-01-05 |
2012-02-28 |
Univ Zuerich |
Method of providing disease-specific binding molecules and targets
|
CA2675379A1
(en)
|
2007-01-12 |
2008-07-17 |
Intercell Ag |
Protective proteins of s. agalactiae, combinations thereof and methods of using the same
|
WO2008098139A2
(en)
|
2007-02-07 |
2008-08-14 |
The Regents Of The University Of Colorado |
Axl tyrosine kinase inhibitors and methods of making and using the same
|
EP2538217A1
(en)
|
2007-02-16 |
2012-12-26 |
Genzyme Corporation |
Method of identifying risk for thyroid disorder
|
LT3067066T
(lt)
|
2007-02-23 |
2019-06-25 |
Prothena Biosciences Limited |
Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas
|
CN101663047B
(zh)
|
2007-02-23 |
2014-07-09 |
纽约哥伦比亚大学理事会 |
通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径来治疗免疫疾病的方法
|
JP5558834B2
(ja)
|
2007-02-23 |
2014-07-23 |
ヤンセン アルツハイマー イミュノセラピー |
シヌクレイノパチーおよびアミロイド形成疾患(amyloidogenicdisease)の予防および処置
|
PT2457928T
(pt)
|
2007-03-13 |
2017-08-17 |
Univ Zuerich |
Anticorpo monoclonal humano específico de tumores
|
GEP20146112B
(en)
|
2007-03-22 |
2014-06-25 |
Ucb Pharma Sa |
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof
|
KR101529334B1
(ko)
|
2007-04-05 |
2015-06-16 |
모르포테크, 인크. |
엔도시알린의 리간드에 대한 결합을 억제하는 방법
|
WO2008134659A2
(en)
|
2007-04-27 |
2008-11-06 |
Zymogenetics, Inc. |
Antagonists to il-17a, il-17f, and il-23p19 and methods of use
|
US8236326B2
(en)
|
2007-05-02 |
2012-08-07 |
Intercell Ag |
Klebsiella antigens
|
EP2160403B1
(en)
|
2007-05-11 |
2018-08-08 |
Genzyme Corporation |
Methods of producing a secreted protein
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
US7709215B2
(en)
|
2007-06-01 |
2010-05-04 |
Cytonics Corporation |
Method for diagnosing and treating acute joint injury
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
DK2170390T3
(en)
|
2007-06-14 |
2019-01-21 |
Biogen Ma Inc |
NATALIZUMABANTISTIC FORMULATIONS
|
EP2167530A2
(en)
|
2007-06-18 |
2010-03-31 |
Intercell AG |
Chlamydia antigens
|
ES2627223T3
(es)
|
2007-06-26 |
2017-07-27 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Presentación de agentes de unión
|
EP2168599B1
(en)
|
2007-06-27 |
2016-08-10 |
Osaka University |
Cancer remedy containing antibody against peptide encoded by exon-17 of periostin
|
EP2014681A1
(en)
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Novel antibodies inhibiting c-met dimerization, and uses thereof
|
JP5932217B2
(ja)
|
2007-07-12 |
2016-06-08 |
ジーアイティーアール, インコーポレイテッド |
Gitr結合分子を使用する併用療法
|
WO2009029342A2
(en)
|
2007-07-13 |
2009-03-05 |
The Johns Hopkins University |
B7-dc variants
|
PL2185198T3
(pl)
|
2007-08-02 |
2015-06-30 |
Gilead Biologics Inc |
Inhibitory LOX i L0XL2 oraz ich zastosowania
|
TWI443109B
(zh)
|
2007-08-30 |
2014-07-01 |
Daiichi Sankyo Co Ltd |
抗epha2抗體
|
WO2009031230A1
(ja)
*
|
2007-09-06 |
2009-03-12 |
Osaka University |
抗cd20モノクローナル抗体
|
EP2197893B1
(en)
|
2007-09-07 |
2013-07-24 |
Dyadic International, Inc. |
Novel fungal enzymes
|
WO2009033743A1
(en)
|
2007-09-13 |
2009-03-19 |
University Of Zurich Prorektorat Forschung |
Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
|
EP2197911A2
(en)
|
2007-09-14 |
2010-06-23 |
Amgen Inc. |
Homogeneous antibody populations
|
AU2008311367B2
(en)
|
2007-10-05 |
2014-11-13 |
Ac Immune S.A. |
Use of anti-amyloid beta antibody in ocular diseases
|
SI2206727T1
(sl)
|
2007-10-11 |
2015-06-30 |
Daiichi Sankyo Company, Limited |
Protitelo, ki cilja osteoklast - soroden protein Siglec-15
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
CN101965365A
(zh)
|
2007-10-19 |
2011-02-02 |
伊缪纳斯制药株式会社 |
能够特异性结合Aβ寡聚体的抗体及其应用
|
US20100303832A1
(en)
|
2007-11-01 |
2010-12-02 |
Hageman Gregory S |
Genes and polymorphisms associated with amd
|
DK2207808T3
(da)
|
2007-11-02 |
2013-08-05 |
Novartis Ag |
Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse
|
CA2703519C
(en)
|
2007-11-09 |
2017-04-18 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
CN103275227B
(zh)
|
2007-11-12 |
2015-02-11 |
U3制药有限公司 |
Axl抗体
|
CN101883858B
(zh)
|
2007-11-28 |
2015-07-22 |
宾夕法尼亚大学托管会 |
猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
|
EP2220217A2
(en)
|
2007-11-28 |
2010-08-25 |
The Trustees of the University of Pennsylvania |
Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
|
WO2009079242A2
(en)
|
2007-12-05 |
2009-06-25 |
Massachusetts Institute Of Technology |
Aglycosylated immunoglobulin mutants
|
RU2559782C2
(ru)
|
2007-12-17 |
2015-08-10 |
Марфл Аб |
Набор для детекции спор, происходящих из микобактерий
|
JPWO2009081955A1
(ja)
|
2007-12-25 |
2011-05-06 |
明治製菓株式会社 |
緑膿菌のiii型分泌装置構成タンパク質pa1698
|
ES2544679T3
(es)
|
2007-12-28 |
2015-09-02 |
Prothena Biosciences Limited |
Tratamiento y profilaxis de la amiloidosis
|
EP2388323B1
(en)
*
|
2008-01-11 |
2016-04-13 |
Gene Techno Science Co., Ltd. |
Humanized anti-9 integrin antibodies and the uses thereof
|
CA2711394A1
(en)
|
2008-01-11 |
2009-07-16 |
Synovex Corporation |
Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
|
JP5440179B2
(ja)
|
2008-01-11 |
2014-03-12 |
アステラス製薬株式会社 |
改良型ヒト化抗ヒトα9インテグリン抗体
|
KR101616136B1
(ko)
|
2008-02-08 |
2016-04-27 |
이무나스 파마 가부시키가이샤 |
Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
|
JP5661476B2
(ja)
|
2008-03-04 |
2015-01-28 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
サルアデノウイルスSAdV−36、−42.1、−42.2および−44ならびにそれらの用途
|
CA2718191C
(en)
|
2008-03-13 |
2018-05-15 |
Biotest Ag |
Agent for treating disease
|
AU2009224690B2
(en)
|
2008-03-13 |
2014-10-09 |
Biotest Ag |
Agent for treating disease
|
KR20100135257A
(ko)
|
2008-03-13 |
2010-12-24 |
바이오테스트 아게 |
질병 치료제
|
EP2275537B1
(en)
|
2008-03-17 |
2014-12-24 |
Livtech Inc. |
Anti-human dlk-1 antibody having anti-tumor activity in vivo
|
CA2718473A1
(en)
|
2008-03-17 |
2009-09-24 |
Intercell Ag |
Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
|
EP2268313A2
(en)
|
2008-03-17 |
2011-01-05 |
Universitätsklinikum Münster |
Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
|
WO2009119794A1
(ja)
|
2008-03-27 |
2009-10-01 |
タカラバイオ株式会社 |
感染症予防、治療剤
|
WO2009126934A2
(en)
|
2008-04-11 |
2009-10-15 |
Seattle Genetics, Inc. |
Detection and tratment of pancreatic, ovarian and other cancers
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
CN102076865B
(zh)
|
2008-05-02 |
2016-03-16 |
西雅图基因公司 |
用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
|
JP2011523560A
(ja)
|
2008-06-02 |
2011-08-18 |
ダナ−ファーバー キャンサー インスティテュート インク. |
Xbp1ペプチド、cd138ペプチドおよびcs1ペプチド
|
WO2009154025A1
(ja)
|
2008-06-20 |
2009-12-23 |
国立大学法人岡山大学 |
酸化LDL/β2GPI複合体に対する抗体及びその用途
|
AU2009264567B2
(en)
|
2008-06-25 |
2014-06-12 |
Novartis Ag |
Humanization of rabbit antibodies using a universal antibody framework
|
ES2890405T3
(es)
|
2008-06-25 |
2022-01-19 |
Novartis Ag |
Humanización de anticuerpos de conejo usando un armazón de anticuerpo universal
|
WO2009155723A2
(en)
|
2008-06-25 |
2009-12-30 |
Esbatech, An Alcon Biomedical Research Unit Llc |
STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
|
CN102164902B
(zh)
|
2008-07-08 |
2014-07-23 |
因塞特公司 |
作为吲哚胺2,3-双加氧酶的抑制剂的1,2,5-噁二唑
|
WO2010104747A2
(en)
|
2009-03-10 |
2010-09-16 |
Baylor Research Institute |
Antigen presenting cell targeted vaccines
|
US8993728B2
(en)
|
2008-07-16 |
2015-03-31 |
Medical And Biological Laboratories Co., Ltd. |
Anti-human CLCP1 antibody and use thereof
|
EP2322220B1
(en)
|
2008-08-01 |
2014-01-01 |
Axis, Inc. |
Therapeutic agent or preventive agent for osteoarthritis
|
US8795981B2
(en)
|
2008-08-08 |
2014-08-05 |
Molecular Devices, Llc |
Cell detection
|
US8417011B2
(en)
|
2008-09-18 |
2013-04-09 |
Molecular Devices (New Milton) Ltd. |
Colony detection
|
EP2172485A1
(en)
|
2008-10-01 |
2010-04-07 |
Pierre Fabre Medicament |
Novel anti CXCR4 antibodies and their use for the treatment of cancer
|
EP2679238A1
(en)
|
2008-10-02 |
2014-01-01 |
Celtaxsys, INC. |
Methods of modulating the negative chemotaxis of immune cells
|
KR20200133324A
(ko)
|
2008-10-09 |
2020-11-27 |
미네르바 바이오테크놀로지 코포레이션 |
세포내에서 다능성을 유도하기 위한 방법
|
EP3199553B1
(en)
|
2008-10-29 |
2019-04-24 |
Circular Commitment Company |
Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
WO2010051367A1
(en)
|
2008-10-31 |
2010-05-06 |
The Trustees Of The University Of Pennsylvania |
Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
US9469691B2
(en)
|
2008-12-02 |
2016-10-18 |
Pierre Fabre Medicament |
Anti-cMET antibody
|
AR074439A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Anticuerpo anti-cmet (receptor c-met)
|
EP2949666B1
(en)
|
2008-12-19 |
2018-12-19 |
Biogen International Neuroscience GmbH |
Human anti-alpha-synuclein antibodies
|
US8313915B2
(en)
|
2009-01-21 |
2012-11-20 |
Gundersen Lutheran Medical Foundation, Inc. |
Early detection of canine lyme disease by specific peptides and antibodies
|
US20100260752A1
(en)
|
2009-01-23 |
2010-10-14 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
|
US20130243779A1
(en)
|
2009-02-05 |
2013-09-19 |
Intercell Ag |
Peptides protective against e. faecalis, methods and uses relating thereto
|
US8617574B2
(en)
|
2009-02-13 |
2013-12-31 |
Valneva Austria Gmbh |
Nontypable Haemophilus influenzae antigens
|
US20110306069A1
(en)
|
2009-02-19 |
2011-12-15 |
Qingyu Wu |
Corin As A Marker For Heart Failure
|
MX2011009439A
(es)
|
2009-03-10 |
2013-06-18 |
Baylor Res Inst |
Vacunas con especificidad de objetivo hacia celula presentadora de antigeno.
|
MX2011009438A
(es)
|
2009-03-10 |
2012-04-02 |
Baylor Res Inst |
Anticuerpos anti-cd40 y usos de los mismos.
|
US9315584B2
(en)
|
2009-03-25 |
2016-04-19 |
Tohoku University |
LH-type bispecific antibody
|
MX343049B
(es)
|
2009-04-09 |
2016-10-21 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
|
AU2010233089B2
(en)
|
2009-04-10 |
2016-05-26 |
Tufts Medical Center, Inc. |
Par-1 activation by metalloproteinase-1 (MMP-1)
|
JP5812418B2
(ja)
|
2009-04-17 |
2015-11-11 |
イムナス・ファーマ株式会社 |
Aβオリゴマーに特異的に結合する抗体およびその利用
|
EP2246364A1
(en)
|
2009-04-29 |
2010-11-03 |
Pierre Fabre Médicament |
Anti CXCR4 antibodies for the treatment of HIV
|
KR101721906B1
(ko)
|
2009-04-29 |
2017-03-31 |
애브비 바이오테크놀로지 리미티드 |
자동 주입 장치
|
EP2270053A1
(en)
|
2009-05-11 |
2011-01-05 |
U3 Pharma GmbH |
Humanized AXL antibodies
|
CA2762203A1
(en)
|
2009-05-29 |
2010-12-02 |
Soumitra Roy |
Simian adenovirus 41 and uses thereof
|
EP2260864A1
(en)
|
2009-06-10 |
2010-12-15 |
University of Melbourne |
Therapeutic applications
|
TWI513465B
(zh)
|
2009-06-25 |
2015-12-21 |
Regeneron Pharma |
以dll4拮抗劑與化學治療劑治療癌症之方法
|
US10087252B2
(en)
|
2009-07-24 |
2018-10-02 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing disease associated with αvβ5 integrin
|
WO2011012646A2
(en)
|
2009-07-28 |
2011-02-03 |
F. Hoffmann-La Roche Ag |
Non-invasive in vivo optical imaging method
|
US20120164659A1
(en)
|
2009-08-05 |
2012-06-28 |
Nexigen Gmbh |
Human hcv-interacting proteins and methods of use
|
WO2011024114A1
(en)
|
2009-08-25 |
2011-03-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Targeting extracellular matrix molecules for the treatment of cancer
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗cdcp1抗體
|
US9005616B2
(en)
|
2009-08-31 |
2015-04-14 |
Amplimmune, Inc. |
Methods and compositions for the inhibition of transplant rejection
|
CA2774326C
(en)
|
2009-09-14 |
2023-11-07 |
Donald Bellgrau |
Modulation of yeast-based immunotherapy products and responses
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
EP2308897A1
(en)
|
2009-10-09 |
2011-04-13 |
Pierre Fabre Medicament |
Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
|
CA2776756A1
(en)
|
2009-10-11 |
2011-04-14 |
Biogen Idec Ma Inc. |
Anti-vla-4 related assays
|
JP5818003B2
(ja)
|
2009-11-18 |
2015-11-18 |
国立大学法人東北大学 |
ヒト型化抗egfr抗体可変領域の高機能性変異体
|
EP2332929A1
(en)
|
2009-11-25 |
2011-06-15 |
ArisGen SA |
Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
US9872905B2
(en)
|
2009-12-01 |
2018-01-23 |
President And Fellows Of Harvard College |
Modulation of NK cell antigen specific effector activity by modulation of CXCR6 (CD186)
|
AU2010330907A1
(en)
|
2009-12-16 |
2012-06-14 |
Bosch, Phillip |
Methods of treating interstitial cystitis
|
WO2011088193A2
(en)
|
2010-01-13 |
2011-07-21 |
University Of Medicine And Dentistry Of New Jersey |
Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency
|
CA2787783A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
US8846397B2
(en)
|
2010-01-20 |
2014-09-30 |
Merck Sharp & Dohme Corp. |
Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
|
CN102811737A
(zh)
|
2010-01-29 |
2012-12-05 |
阿克西斯股份有限公司 |
骨关节炎治疗及预防药物组合物和上述组合物的制造方法
|
JP2012246222A
(ja)
|
2010-01-29 |
2012-12-13 |
Axis Inc |
変形性関節症治療剤または予防剤を製造するための使用
|
KR101684246B1
(ko)
|
2010-01-29 |
2016-12-08 |
가부시키가이샤 아크시스 |
변형성 관절증 치료제를 포함하는 주사제
|
CA2789168A1
(en)
|
2010-02-02 |
2011-08-11 |
Abbott Biotechnology Ltd. |
Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
|
TWI504410B
(zh)
|
2010-02-08 |
2015-10-21 |
Agensys Inc |
結合至161p2f10b蛋白之抗體藥物結合物(adc)
|
RU2565539C2
(ru)
|
2010-02-18 |
2015-10-20 |
Те Риджентс Оф Те Юниверсити Оф Калифорния |
АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8
|
WO2011109398A2
(en)
|
2010-03-02 |
2011-09-09 |
President And Fellows Of Harvard College |
Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
|
CN102858796B
(zh)
*
|
2010-03-03 |
2016-05-11 |
不列颠哥伦比亚大学 |
寡聚体特异性淀粉样蛋白β表位和抗体
|
EP2553449A2
(en)
|
2010-03-26 |
2013-02-06 |
Westfälische Wilhelms-Universität Münster |
Substitute therapy for glucocorticoids
|
EP2371863A1
(en)
|
2010-03-30 |
2011-10-05 |
Pierre Fabre Médicament |
Humanized anti CXCR4 antibodies for the treatment of cancer
|
WO2011127412A2
(en)
|
2010-04-09 |
2011-10-13 |
Critical Care Diagnostics, Inc. |
Soluble human st-2 antibodies and assays
|
LT2558499T
(lt)
|
2010-04-16 |
2017-07-25 |
Biogen Ma Inc. |
Antikūnai prieš vla-4
|
KR101850687B1
(ko)
|
2010-04-21 |
2018-04-20 |
애브비 바이오테크놀로지 리미티드 |
치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스
|
RU2012148816A
(ru)
|
2010-05-07 |
2014-06-20 |
Ф. Хоффманн-Ля Рош Аг |
Метод диагностики для определения клеток ex vivo
|
EA201500220A1
(ru)
|
2010-05-17 |
2015-10-30 |
Ливтех, Инк. |
Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
WO2012005076A1
(ja)
|
2010-07-08 |
2012-01-12 |
本田技研工業株式会社 |
高周波加熱用コイル
|
EP2593475B1
(en)
|
2010-07-14 |
2016-03-02 |
Merck Sharp & Dohme Corp. |
Anti-addl monoclonal antibody and uses thereof
|
SI2593128T1
(en)
|
2010-07-15 |
2018-08-31 |
Adheron Therapeutics, Inc. |
Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures
|
CN103221422B
(zh)
|
2010-07-29 |
2017-03-29 |
十一生物治疗股份有限公司 |
嵌合il‑1受体i型激动剂和拮抗剂
|
CA2806909C
(en)
|
2010-07-30 |
2019-12-17 |
Ac Immune S.A. |
Safe and functional humanized antibodies
|
JP2012034668A
(ja)
|
2010-08-12 |
2012-02-23 |
Tohoku Univ |
ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用
|
WO2012027494A1
(en)
|
2010-08-24 |
2012-03-01 |
Regents Of The University Of Minnesota |
Bispecific targeting reagents
|
WO2012025633A1
(en)
|
2010-08-27 |
2012-03-01 |
University Of Zurich |
A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
|
US9034333B2
(en)
|
2010-08-27 |
2015-05-19 |
University Of Zurich |
Method for target and drug validation in inflammatory and/or cardiovascular diseases
|
WO2012028697A1
(en)
|
2010-09-01 |
2012-03-08 |
Eth Zürich, Institute Of Molecular Biology And Biophysics |
Affinity purification system based on donor strand complementation
|
US20120244141A1
(en)
|
2010-09-28 |
2012-09-27 |
Boehringer Ingelheim International Gmbh |
Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
|
US9675693B2
(en)
|
2010-09-30 |
2017-06-13 |
Riken |
Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma
|
US8497138B2
(en)
|
2010-09-30 |
2013-07-30 |
Genetix Limited |
Method for cell selection
|
WO2012049570A1
(en)
|
2010-10-11 |
2012-04-19 |
Panima Pharmaceuticals Ag |
Human anti-tau antibodies
|
EP2627356B1
(en)
|
2010-10-13 |
2019-05-22 |
Janssen Biotech, Inc. |
Human oncostatin m antibodies and methods of use
|
CA2813796C
(en)
|
2010-10-18 |
2019-01-15 |
Mediapharma S.R.L. |
Erbb3 binding antibody
|
ES2730941T7
(es)
|
2010-10-22 |
2020-05-27 |
Seattle Genetics Inc |
Efectos sinérgicos entre los conjugados de conjugados anticuerpo-fármaco a base de auristatina e inhibidores de la ruta PI3K-AKT-mTOR
|
UY33679A
(es)
|
2010-10-22 |
2012-03-30 |
Esbatech |
Anticuerpos estables y solubles
|
EP2632492B1
(en)
|
2010-10-25 |
2017-10-04 |
Biogen MA Inc. |
METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
|
KR20140009174A
(ko)
|
2010-10-27 |
2014-01-22 |
피에르 파브르 메디카먼트 |
Hiv의 치료를 위한 항체들
|
RS54846B1
(sr)
|
2010-10-29 |
2016-10-31 |
Daiichi Sankyo Co Ltd |
Novo anti-dr5 antitelo
|
WO2012068463A2
(en)
|
2010-11-18 |
2012-05-24 |
Beth Israel Deaconess Medicall Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
|
SG10201509499RA
(en)
|
2010-11-19 |
2015-12-30 |
Eisai R&D Man Co Ltd |
Neutralizing anti-ccl20 antibodies
|
EP2643465B1
(en)
|
2010-11-23 |
2016-05-11 |
The Trustees Of The University Of Pennsylvania |
Subfamily e simian adenovirus a1321 and uses thereof
|
EP3628689A1
(en)
|
2010-12-17 |
2020-04-01 |
Neurimmune Holding AG |
Human anti-sod1 antibodies
|
WO2012090939A1
(ja)
|
2010-12-27 |
2012-07-05 |
国立大学法人名古屋大学 |
受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法
|
PT2663580T
(pt)
|
2011-01-10 |
2017-03-10 |
Univ Zuerich |
Terapêutica de associação incluindo anticorpos de ligação a antigénios associados a tumores
|
US9217040B2
(en)
|
2011-01-14 |
2015-12-22 |
The Regents Of The University Of California |
Therapeutic antibodies against ROR-1 protein and methods for use of same
|
EP4245219A3
(en)
|
2011-01-24 |
2023-11-01 |
AbbVie Biotechnology Ltd. |
Automatic injection devices having overmolded gripping surfaces
|
WO2012104824A1
(en)
|
2011-02-04 |
2012-08-09 |
Ecole polytechnique fédérale de Lausanne (EPFL) |
Therapeutic antibodies targeting app-c99
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
WO2012110843A1
(en)
|
2011-02-18 |
2012-08-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
|
WO2012113775A1
(en)
|
2011-02-21 |
2012-08-30 |
University Of Zurich |
Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
|
EP2683413A1
(en)
|
2011-03-07 |
2014-01-15 |
F.Hoffmann-La Roche Ag |
In vivo selection of therapeutically active antibodies
|
WO2012119999A1
(en)
|
2011-03-07 |
2012-09-13 |
F. Hoffmann-La Roche Ag |
Means and methods for in vivo testing of therapeutic antibodies
|
WO2012120130A1
(en)
|
2011-03-09 |
2012-09-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods to characterize patients suffering from hemolysis
|
WO2012125680A1
(en)
|
2011-03-16 |
2012-09-20 |
Novartis Ag |
Methods of treating vasculitis using an il-17 binding molecule
|
JP5955871B2
(ja)
|
2011-03-17 |
2016-07-20 |
ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Tcrアルファ/ベータを枯渇させた細胞調製物
|
US20120301465A1
(en)
|
2011-03-25 |
2012-11-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Compositions and methods to immunize against hepatitis c virus
|
TW201249867A
(en)
|
2011-04-01 |
2012-12-16 |
Astellas Pharma Inc |
Novel anti-human il-23 receptor antibody
|
US9956345B2
(en)
|
2011-04-21 |
2018-05-01 |
Abbvie Inc. |
Wearable automatic injection device for controlled administration of therapeutic agents
|
RS57279B1
(sr)
|
2011-04-25 |
2018-08-31 |
Daiichi Sankyo Co Ltd |
Anti-b7-h3 antitelo
|
KR102014512B1
(ko)
|
2011-05-02 |
2019-08-26 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
항-α4β7 항체에 대한 제형
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
EP2707711A1
(en)
|
2011-05-09 |
2014-03-19 |
The Cleveland Clinic Foundation |
Serum s100b and uses thereof
|
WO2012163848A1
(en)
|
2011-05-27 |
2012-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of crohn's disease
|
EP2530088A1
(en)
|
2011-05-30 |
2012-12-05 |
Klinikum rechts der Isar der Technischen Universität München |
Means and methods for diagnosing and treating multiple sclerosis
|
WO2012163771A1
(en)
|
2011-06-03 |
2012-12-06 |
Ct Atlantic Ltd. |
Magea3 binding antibodies
|
WO2012163769A1
(en)
|
2011-06-03 |
2012-12-06 |
Ct Atlantic Ltd. |
Magea3 binding antibodies
|
JP6305919B2
(ja)
|
2011-06-06 |
2018-04-04 |
プロセナ バイオサイエンシーズ リミテッド |
Mcamアンタゴニスト及び治療の方法
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
DK2723379T3
(en)
|
2011-06-23 |
2018-10-15 |
Biogen Int Neuroscience Gmbh |
ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
|
DE202011103324U1
(de)
|
2011-07-12 |
2012-01-02 |
Nekonal S.A.R.L. |
Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
EP2737083A1
(en)
|
2011-07-27 |
2014-06-04 |
INSERM (Institut National de la Santé et de la Recherche Scientifique) |
Methods for diagnosing and treating myhre syndrome
|
ME02944B
(me)
|
2011-08-11 |
2018-04-20 |
Astellas Pharma Inc |
Novo antitelo protiv humanog ngf
|
EP2743699A4
(en)
|
2011-08-12 |
2015-04-08 |
Nat Inst Infectious Diseases |
METHOD FOR THE TEST, PREVENTION AND TREATMENT OF ASPERGILLUS FUMIGATUS INFECTIOUS DISEASE, AND COMPOSITION
|
US20140271680A1
(en)
|
2011-08-12 |
2014-09-18 |
Universite Paris-Est Creteil Val De Marne |
Methods and pharmaceutical compositions for treatment of pulmonary hypertension
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
CN109265543B
(zh)
|
2011-09-19 |
2022-04-26 |
阿克松神经系统科学公司 |
阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
|
GB2495115A
(en)
*
|
2011-09-29 |
2013-04-03 |
Oxford Plastic Sys Ltd |
Base for supporting temporary fence panels or posts.
|
AR088048A1
(es)
|
2011-10-04 |
2014-05-07 |
Univ Columbia |
Señuelos notch1 humanos
|
WO2013050441A1
(en)
|
2011-10-05 |
2013-04-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
|
US20140248294A1
(en)
|
2011-10-05 |
2014-09-04 |
University Of Bremen |
Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
US10378060B2
(en)
|
2011-10-14 |
2019-08-13 |
Dana-Farber Cancer Institute, Inc. |
ZNF365/ZFP365 biomarker predictive of anti-cancer response
|
CN103998598A
(zh)
|
2011-10-17 |
2014-08-20 |
米纳瓦生物技术公司 |
用于干细胞增殖和诱导的培养基
|
WO2013057313A1
(en)
|
2011-10-20 |
2013-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the detection and the treatment of cardiac remodeling
|
EP2589609A1
(en)
|
2011-11-03 |
2013-05-08 |
Pierre Fabre Medicament |
Antigen binding protein and its use as addressing product for the treatment of cancer
|
US9427464B2
(en)
|
2011-11-22 |
2016-08-30 |
Chiome Bioscience Inc. |
Anti-human TROP-2 antibody having an antitumor activity in vivo
|
AU2012342482A1
(en)
|
2011-11-22 |
2014-05-22 |
Cnrs (Centre National De La Recherche Scientifique) |
Methods and pharmaceutical compositions for reducing airway hyperresponse
|
JP6082402B2
(ja)
|
2011-11-28 |
2017-02-15 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
加齢に伴う機能障害の処置に使用するための薬学的組成物
|
EP2602621A1
(en)
|
2011-12-08 |
2013-06-12 |
Julius-Maximilians-Universität Würzburg |
LASP-1, a novel urinary marker for transitional cell carcinoma detection
|
BR112014014258A2
(pt)
*
|
2011-12-13 |
2020-10-27 |
Nordic Nanovector As. |
molécula de anticorpo que se liga a cd37 humano; anticorpo; molécula de dna; vetor de expressão; célula hospedeira; método para produzir um anticorpo; composição farmacêutica; método de esgotamento de células b que expressam cd37 dentre uma população de células; radioimunoconjugado que se liga a cd37 humano; método de tratamento de uma malignidade de célula b; kit para a produção do radioimunoconjugado; e preparação injetável de anticorpo hh1 quimérico ou humanizado para uso no pré-tratamento de uma malignidade de célula b
|
FR2984750B1
(fr)
|
2011-12-23 |
2014-01-10 |
Lfb Biotechnologies |
Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
|
US20150030602A1
(en)
|
2011-12-23 |
2015-01-29 |
Phenoquest Ag |
Antibodies for the treatment and diagnosis of affective and anxiety disorders
|
CA2861793C
(en)
|
2011-12-28 |
2023-08-01 |
Immunoqure Ag |
Method of providing monoclonal auto-antibodies with desired specificity
|
SG11201403756PA
(en)
|
2012-01-01 |
2014-11-27 |
Qbi Entpr Ltd |
Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
|
AU2013216863B2
(en)
|
2012-02-10 |
2018-09-06 |
Seagen Inc. |
Detection and treatment of CD30+ cancers
|
JP6345123B2
(ja)
|
2012-02-16 |
2018-06-20 |
サンタラス, インコーポレイテッド |
抗vla1(cd49a)抗体医薬組成物
|
EP2817340B1
(en)
|
2012-02-23 |
2020-12-09 |
Daiichi Sankyo Europe GmbH |
Her3 inhibitor for modulating radiosensitivity
|
WO2013129454A1
(ja)
|
2012-02-28 |
2013-09-06 |
アステラス製薬株式会社 |
新規抗ヒトil-23受容体抗体
|
MY175224A
(en)
|
2012-03-15 |
2020-06-16 |
Janssen Biotech Inc |
Human anti-cd27 antibodies, methods, and uses
|
ES2731757T3
(es)
|
2012-03-20 |
2019-11-18 |
Biogen Ma Inc |
Anticuerpos neutralizantes de JCV
|
KR20150003170A
(ko)
|
2012-03-30 |
2015-01-08 |
다이이찌 산쿄 가부시키가이샤 |
CDR 개변 항 Siglec-15 항체
|
CN104321430A
(zh)
|
2012-03-30 |
2015-01-28 |
第一三共株式会社 |
新颖的抗-siglec-15抗体
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
EP2833900B1
(en)
|
2012-04-01 |
2018-09-19 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
EP2834641A1
(en)
|
2012-04-02 |
2015-02-11 |
Gundersen Lutheran Health Systems, Inc. |
Reagents, methods, and kits for the classification of cancer
|
BR112014025037A2
(ja)
|
2012-04-09 |
2018-07-31 |
Daiichi Sankyo Company, Limited |
Anti-FGFR2 antibody
|
RU2682451C2
(ru)
|
2012-04-27 |
2019-03-19 |
Дайичи Санкио Компани, Лимитед |
Антитела к robo4
|
US9062120B2
(en)
|
2012-05-02 |
2015-06-23 |
Janssen Biotech, Inc. |
Binding proteins having tethered light chains
|
CN104470950B
(zh)
|
2012-05-11 |
2017-04-26 |
公益财团法人微生物化学研究会 |
抗cxadr抗体
|
BR112014028306A2
(pt)
|
2012-05-15 |
2018-04-17 |
Morphotek, Inc. |
métodos para tratamento de câncer gástrico.
|
SG10201609511XA
(en)
|
2012-05-18 |
2016-12-29 |
Univ Pennsylvania |
Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
|
JP2015520373A
(ja)
|
2012-05-22 |
2015-07-16 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
巣状分節性糸球体硬化症を診断及び処置するための方法
|
KR101937733B1
(ko)
|
2012-05-24 |
2019-01-11 |
마운트게이트 그룹 리미티드 |
광견병 감염의 방지 및 치료에 관한 조성물 및 방법
|
WO2014011984A1
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Toxicity management for anti-tumor activity of cars
|
US20150184155A1
(en)
|
2012-07-18 |
2015-07-02 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for preventing and treating chronic kidney disease (ckd)
|
US9181343B2
(en)
|
2012-07-19 |
2015-11-10 |
Redwood Bioscience Inc. |
Antibody specific for CD22 and methods of use thereof
|
WO2014021339A1
(ja)
|
2012-07-30 |
2014-02-06 |
国立大学法人名古屋大学 |
ヒトミッドカインに対するモノクローナル抗体
|
CN104662044B
(zh)
|
2012-08-24 |
2018-10-30 |
加利福尼亚大学董事会 |
用于治疗ror1癌症并抑制转移的抗体和疫苗
|
TWI595007B
(zh)
|
2012-09-10 |
2017-08-11 |
Neotope Biosciences Ltd |
抗mcam抗體及相關使用方法
|
CN104797132B
(zh)
|
2012-09-13 |
2017-06-30 |
中外制药株式会社 |
基因敲入非人动物
|
EP2711016A1
(en)
|
2012-09-21 |
2014-03-26 |
Covagen AG |
Novel IL-17A binding molecules and medical uses thereof
|
PT2905335T
(pt)
|
2012-10-03 |
2018-03-12 |
Chiome Bioscience Inc |
Anticorpo anti-hdlk-1 tendo uma atividade anti-tumoral in vivo
|
JP2015533127A
(ja)
|
2012-10-08 |
2015-11-19 |
セント ジュード チルドレンズ リサーチ ホスピタルSt. Jude Children’s Research Hospital |
ニューロピリン1:セマフォリン軸を介した、制御性t細胞の安定性および機能の制御に基づく療法
|
KR102087017B1
(ko)
|
2012-10-11 |
2020-03-10 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트
|
DE102012020496A1
(de)
|
2012-10-18 |
2014-04-24 |
Charité - Universitätsmedizin Berlin |
Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
|
EP2910573B1
(en)
|
2012-10-19 |
2020-02-19 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
EP2911681A1
(en)
|
2012-10-26 |
2015-09-02 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
|
EP2914628A1
(en)
|
2012-11-01 |
2015-09-09 |
Max-Delbrück-Centrum für Molekulare Medizin |
An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
BR112015010046B1
(pt)
|
2012-11-05 |
2023-05-02 |
Pierre Fabre Medicament |
Proteínas de ligação a antígeno ou um fragmento de ligação a antígeno da mesma e seu método de produção, vetor, célula hospedeira de microrganismo transgênico, imunoconjugado e seu uso, composição farmacêutica e hibridoma murino
|
JP6445446B2
(ja)
|
2012-11-08 |
2018-12-26 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
骨転移の治療のための方法及び医薬組成物
|
TW201438736A
(zh)
|
2012-11-14 |
2014-10-16 |
Regeneron Pharma |
以dll4拮抗劑治療卵巢癌之方法
|
AU2013359419B2
(en)
|
2012-12-10 |
2018-03-15 |
Biogen Ma Inc. |
Anti-blood dendritic cell antigen 2 antibodies and uses thereof
|
WO2014096672A1
(fr)
|
2012-12-17 |
2014-06-26 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
|
US10024844B2
(en)
|
2012-12-20 |
2018-07-17 |
Hospital For Special Surgery |
Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
|
LT2935326T
(lt)
|
2012-12-21 |
2020-12-10 |
Biogen Ma Inc. |
Žmogaus antikūnai prieš tau baltymą
|
CA2896824A1
(en)
|
2012-12-31 |
2014-07-03 |
Neurimmune Holding Ag |
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
|
EP2752426A1
(en)
|
2013-01-03 |
2014-07-09 |
Covagen AG |
Human serum albumin binding compounds and fusion proteins thereof
|
WO2014115430A1
(ja)
|
2013-01-28 |
2014-07-31 |
株式会社イーベック |
ヒト化抗hmgb1抗体もしくはその抗原結合性断片
|
EP2951589A1
(en)
|
2013-02-01 |
2015-12-09 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods for predicting and preventing metastasis in triple negative breast cancers
|
EP2955226B1
(en)
|
2013-02-08 |
2019-06-26 |
Medical & Biological Laboratories Co., Ltd. |
Antibodies to human nrg1 protein
|
WO2014124677A1
(en)
|
2013-02-15 |
2014-08-21 |
Esbatech - A Novartis Company Llc |
Acceptor framework for cdr grafting
|
EP2958939A1
(en)
|
2013-02-20 |
2015-12-30 |
ESBATech - a Novartis Company LLC |
Acceptor framework for cdr grafting
|
FR3004184B1
(fr)
|
2013-02-26 |
2016-03-18 |
Agronomique Inst Nat Rech |
Anticorps anti-gluten desamide et utilisations.
|
ES2673583T3
(es)
|
2013-02-28 |
2018-06-22 |
National Cancer Center |
Anticuerpo contra fibrina insoluble
|
US10227396B2
(en)
|
2013-03-08 |
2019-03-12 |
Osaka University |
Antibody against peptide encoded by Exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
EP2968468B1
(en)
|
2013-03-13 |
2021-07-14 |
Buzzard Pharmaceuticals AB |
Chimeric cytokine formulations for ocular delivery
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
EP2968550B1
(en)
|
2013-03-14 |
2018-11-14 |
Ffe Therapeutics LLC |
Compositions and methods for treating angiogenesis-related disorders
|
WO2014143739A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
CN105392801A
(zh)
|
2013-03-15 |
2016-03-09 |
比奥根Ma公司 |
使用抗αvβ5抗体治疗和预防急性肾损伤
|
WO2014144466A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
PT2976361T
(pt)
|
2013-03-18 |
2018-10-19 |
Janssen Pharmaceuticals Inc |
Anticorpos anti-cd134 (ox40) humanizados e utilizações dos mesmos
|
WO2014165524A2
(en)
|
2013-04-01 |
2014-10-09 |
The Regents Of The University Of California |
Methods and compositions for treating and preventing disease associated with avb8 integrin
|
WO2014174596A1
(ja)
|
2013-04-23 |
2014-10-30 |
株式会社医学生物学研究所 |
ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
CN107460201A
(zh)
|
2013-05-08 |
2017-12-12 |
科济生物医药(上海)有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
CA2952390A1
(en)
|
2013-06-20 |
2014-12-24 |
The Trustees Of The University Of Pennsylvania |
Methods for diagnosing pancreatic cancer
|
US10112995B2
(en)
|
2013-07-03 |
2018-10-30 |
Immunoqure Ag |
Human anti-IFN-α antibodies
|
EP3016973A1
(en)
|
2013-07-05 |
2016-05-11 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
EP3708189B1
(en)
|
2013-07-05 |
2023-11-29 |
University of Washington through its Center for Commercialization |
Soluble mic neutralizing monoclonal antibody for treating cancer
|
LT3031913T
(lt)
|
2013-08-09 |
2019-05-27 |
Astellas Pharma Inc. |
Naujas antikūnas, atpažįstantis žmogaus tslp receptorių
|
EP3055695A1
(en)
|
2013-09-12 |
2016-08-17 |
Institut National de la Santé et de la Recherche Médicale |
Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies
|
WO2015040215A1
(en)
|
2013-09-20 |
2015-03-26 |
Westfaelische Wilhelms-Universitaet Muenster |
Cell-penetrating bacterial e3-ubiqitin-ligases for use in immunotherapy
|
JP6615100B2
(ja)
|
2013-09-24 |
2019-12-04 |
ザ ファインスタイン インスティチュート フォー メディカル リサーチ |
低温誘導性rna結合タンパク質活性を阻害するペプチド
|
US9974788B2
(en)
|
2013-09-26 |
2018-05-22 |
Beth Israel Deaconess Medical Center, Inc. |
Inhibition of SGK1 in the treatment of heart conditions
|
CA2925897A1
(en)
|
2013-09-30 |
2015-04-02 |
Daiichi Sankyo Company, Limited |
Anti-lps o11 antibody
|
ES2714708T3
(es)
|
2013-10-01 |
2019-05-29 |
Mayo Found Medical Education & Res |
Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
|
ES2768618T3
(es)
|
2013-10-08 |
2020-06-23 |
Daiichi Sankyo Co Ltd |
Combinación de anticuerpo anti-FGFR2 y otro agente
|
UA119973C2
(uk)
|
2013-11-06 |
2019-09-10 |
Янссен Байотек, Інк. |
Антитіло до ссl17
|
US20160264648A1
(en)
|
2013-11-06 |
2016-09-15 |
Osaka University |
Antibody having broad neutralization activity against group 1 influenza a viruses
|
WO2015071701A1
(en)
|
2013-11-15 |
2015-05-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of pancreatic cancers
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
WO2015098813A1
(ja)
|
2013-12-24 |
2015-07-02 |
アステラス製薬株式会社 |
新規抗ヒトbdca-2抗体
|
EP3088419B1
(en)
|
2013-12-25 |
2018-10-10 |
Daiichi Sankyo Company, Limited |
Anti-trop2 antibody-drug conjugate
|
AU2015205327B2
(en)
|
2014-01-09 |
2019-02-14 |
Hadasit Medical Research Services And Development Ltd. |
Improved cell compositions and methods for cancer therapy
|
US10286058B2
(en)
|
2014-01-13 |
2019-05-14 |
Baylor Research Institute |
Vaccines against HPV and HPV-related diseases
|
CN104774264B
(zh)
|
2014-01-15 |
2018-09-14 |
上海易乐生物技术有限公司 |
抗人proBDNF单克隆抗体及其在疼痛中的作用
|
SG11201603960XA
(en)
|
2014-01-31 |
2016-07-28 |
Daiichi Sankyo Co Ltd |
Anti-her2 antibody-drug conjugate
|
JP6666848B2
(ja)
|
2014-02-18 |
2020-03-18 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Nrp−1/obr複合体シグナル伝達経路により媒介される疾患の処置のための方法及び医薬組成物
|
WO2015124570A1
(en)
|
2014-02-18 |
2015-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of influenza a virus infection
|
EP3415160B1
(en)
|
2014-03-04 |
2021-08-18 |
Klinikum der Universität München |
Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies
|
WO2015140351A1
(en)
|
2014-03-21 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing myelination
|
US20170174764A1
(en)
|
2014-03-27 |
2017-06-22 |
Yeda Research And Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
CN111228511B
(zh)
|
2014-04-10 |
2024-06-18 |
第一三共株式会社 |
抗her3抗体-药物偶联物
|
WO2015164743A2
(en)
|
2014-04-24 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
MA39909B1
(fr)
|
2014-04-25 |
2019-05-31 |
Pf Medicament |
Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
|
LT3134125T
(lt)
|
2014-04-25 |
2020-01-10 |
Pierre Fabre Médicament |
Antikūno ir vaisto konjugatas bei jo panaudojimas vėžio gydymui
|
ES2841249T3
(es)
|
2014-04-25 |
2021-07-07 |
Pf Medicament |
Anticuerpo IGF-1R y su utilización como un vehículo de direccionamiento para el tratamiento del cáncer
|
MD20160130A2
(ro)
|
2014-04-27 |
2017-04-30 |
Ccam Biotherapeutics Ltd. |
Anticorpi umanizaţi contra CEACAM1
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
JP6791763B2
(ja)
|
2014-06-26 |
2020-11-25 |
イェール ユニバーシティーYale University |
疾患および障害の処置においてレナラーゼを制御する組成物および方法
|
WO2016011383A1
(en)
|
2014-07-17 |
2016-01-21 |
The Trustees Of The University Of Pennsylvania |
Methods for using exosomes to monitor transplanted organ status
|
CN112979828A
(zh)
|
2014-07-17 |
2021-06-18 |
恺兴生命科技(上海)有限公司 |
靶向cld18a2的t淋巴细胞及其制备方法和应用
|
EP3171896A4
(en)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
SG10201902850TA
(en)
|
2014-09-30 |
2019-04-29 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (dprs) antibody
|
CA2963470A1
(en)
|
2014-10-03 |
2016-04-07 |
Massachusetts Institute Of Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
WO2016057367A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
US10806773B2
(en)
|
2014-10-09 |
2020-10-20 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable IL-2 dose regimen for treating immune disorders
|
ES2832802T3
(es)
|
2014-11-21 |
2021-06-11 |
Univ Maryland |
Sistemas de administración dirigida del particulado específico de una estructura
|
US20170319661A1
(en)
|
2014-12-03 |
2017-11-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers
|
US20180031579A1
(en)
|
2015-02-12 |
2018-02-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
|
CA2977532A1
(en)
|
2015-03-06 |
2016-09-15 |
Dana-Farber Cancer Institute, Inc. |
Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
|
EP3067062A1
(en)
|
2015-03-13 |
2016-09-14 |
Ipsen Pharma S.A.S. |
Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
|
AU2016232749B2
(en)
|
2015-03-18 |
2021-09-23 |
The Johns Hopkins University |
Novel monoclonal antibody inhibitors targeting potassium channel KCNK9
|
ES2805743T3
(es)
|
2015-03-24 |
2021-02-15 |
Inst Nat Sante Rech Med |
Método y composición farmacéutica para uso en el tratamiento de la diabetes
|
US10214591B1
(en)
|
2015-04-03 |
2019-02-26 |
Alienor Farma |
Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
|
EP3283108B1
(en)
|
2015-04-13 |
2020-10-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
|
JP2018519248A
(ja)
|
2015-04-22 |
2018-07-19 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Th17媒介性疾患の処置のための方法及び医薬組成物
|
CA2987877A1
(en)
|
2015-06-01 |
2016-12-08 |
Medigene Immunotherapies Gmbh |
T-cell receptor specific antibodies
|
AU2016273214B2
(en)
|
2015-06-01 |
2018-10-18 |
Medigene Immunotherapies Gmbh |
Method for generating antibodies against T cell receptor
|
WO2016193299A1
(en)
|
2015-06-01 |
2016-12-08 |
Medigene Immunotherapies Gmbh |
T cell receptor library
|
EP3954394A1
(en)
|
2015-06-19 |
2022-02-16 |
Centurion BioPharma Corporation |
Delivery systems for controlled drug release
|
US20180161429A1
(en)
|
2015-06-26 |
2018-06-14 |
Beth Israel Deaconess Medical Center Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
BR112017027690A2
(pt)
|
2015-06-29 |
2018-10-09 |
Daiichi Sankyo Co Ltd |
método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
|
EA201890434A1
(ru)
|
2015-08-05 |
2018-10-31 |
Янссен Байотек, Инк. |
Антитела к cd154 и способы их применения
|
WO2017046335A1
(en)
|
2015-09-18 |
2017-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
|
ES2940360T3
(es)
|
2015-09-22 |
2023-05-05 |
Inst Nat Sante Rech Med |
Polipéptidos capaces de inhibir la unión entre leptina y neuropilina-1
|
IL302932A
(en)
|
2015-09-24 |
2023-07-01 |
Daiichi Sankyo Co Ltd |
Antibodies against GARP, nucleotides encoding them, and vectors, cells and preparations containing them, methods for their preparation and uses thereof
|
BR112018006360A2
(pt)
|
2015-09-30 |
2018-10-09 |
Janssen Biotech Inc |
anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
|
JP6857360B2
(ja)
|
2015-10-08 |
2021-04-14 |
国立大学法人東海国立大学機構 |
キメラ抗原受容体を発現する遺伝子改変t細胞の調製方法
|
WO2017064716A1
(en)
|
2015-10-13 |
2017-04-20 |
Rappaport Family Institute For Research |
Heparanase-neutralizing monoclonal antibodies
|
US20180305458A1
(en)
|
2015-10-16 |
2018-10-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
|
US10858423B2
(en)
|
2015-10-26 |
2020-12-08 |
Pierre Fabre Medicament |
Composition for the treatment of IGF-1R expressing cancer
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
ITUB20155272A1
(it)
|
2015-11-02 |
2017-05-02 |
Scuola Normale Superiore |
Intracellular antibody
|
JP2019503985A
(ja)
|
2015-11-03 |
2019-02-14 |
グリコミメティクス, インコーポレイテッド |
モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法
|
KR20180069070A
(ko)
|
2015-11-03 |
2018-06-22 |
얀센 바이오테크 인코포레이티드 |
Tim-3과 특이적으로 결합하는 항체 및 그의 용도
|
ITUB20155097A1
(it)
|
2015-11-05 |
2017-05-05 |
Biouniversa Srl |
Anticorpi umanizzati anti-BAG3
|
US10829562B2
(en)
|
2015-12-10 |
2020-11-10 |
Katholieke Universiteit Leuven |
Haemorrhagic disorder due to ventricular assist device
|
BR112018012344A2
(pt)
|
2015-12-17 |
2018-12-04 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a hla-dr e seus usos
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
DK3394247T3
(da)
|
2015-12-23 |
2021-04-12 |
Medigene Immunotherapies Gmbh |
Ny generering af antigen-specifikke tcr'er
|
ES2899360T3
(es)
|
2015-12-31 |
2022-03-11 |
Progastrine Et Cancers S A R L |
Composiciones y procedimientos para detectar y tratar cáncer gástrico
|
PL3397967T3
(pl)
|
2015-12-31 |
2021-06-28 |
Progastrine Et Cancers S.À R.L. |
Kompozycje i sposoby do wykrywania i leczenia raka przełyku
|
WO2017114972A1
(en)
|
2015-12-31 |
2017-07-06 |
Progastrine Et Cancers S.À R.L. |
Compositions and methods for detecting and treating ovarian cancer
|
EP3202788A1
(en)
|
2016-02-05 |
2017-08-09 |
MediaPharma S.r.l. |
Endosialin-binding antibody
|
US11484577B2
(en)
|
2016-02-15 |
2022-11-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
|
EP3205663A1
(en)
|
2016-02-15 |
2017-08-16 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for inhibiting gene expression
|
US10906987B2
(en)
|
2016-03-01 |
2021-02-02 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to human poliovirus receptor (PVR)
|
US11340233B2
(en)
|
2016-03-07 |
2022-05-24 |
Pierre Fabre Medicament |
Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
|
US11921116B2
(en)
|
2016-03-09 |
2024-03-05 |
Memorial Sloan Kettering Cancer Center |
Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
|
DK3430404T3
(da)
|
2016-03-15 |
2022-03-21 |
Inst Nat Sante Rech Med |
Tidlig og non-invasiv fremgangsmåde til vurdering af et individs risiko for at få duktalt adenokarcinom i bugspytkirtlen og fremgangsmåder til behandling af en sådan sygdom
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
US20190086392A1
(en)
|
2016-03-21 |
2019-03-21 |
Inserm (Institut National De La Sante Et De La Recherch Medicale) |
Methods for diagnosis and treatment of solar lentigo
|
RU2744959C2
(ru)
|
2016-03-23 |
2021-03-17 |
Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд |
Новые анти-pd-l1 антитела
|
PE20190175A1
(es)
|
2016-03-28 |
2019-02-01 |
Incyte Corp |
Compuestos de pirrolotriazina como inhibidores de tam
|
ITUA20162242A1
(it)
|
2016-04-01 |
2017-10-01 |
St Biochimico Italiano Giovanni Lorenzini Spa |
Un nuovo anticorpo anti-erbb2
|
PT3445785T
(pt)
|
2016-04-18 |
2022-09-21 |
Faron Pharmaceuticals Oy |
Anticorpos anti clever-1 humanizados e sua utilização
|
ES2941693T3
(es)
|
2016-05-03 |
2023-05-24 |
Inst Nat Sante Rech Med |
Métodos y composiciones farmacéuticas para el tratamiento de lesiones tisulares
|
EP4067493A1
(en)
|
2016-05-11 |
2022-10-05 |
Amgen Inc. |
Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
|
DE102017110958A1
(de)
|
2016-05-20 |
2017-11-23 |
Christoph Karl |
Pharmazeutische Zusammensetzungen mit Anti-RANKL-Antikörpern, Kalzium und Vitamin D, geeignet zur Behandlung und/oder Prophylaxe von Erkrankungen des Knochenstoffwechsels und von therapiebedingten Hypokalzämien
|
EP3464357A1
(en)
|
2016-05-24 |
2019-04-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
|
WO2017202814A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
|
US20190307797A1
(en)
|
2016-06-07 |
2019-10-10 |
Maax-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Chimeric antigen receptor and car-t cells that bind bcma
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
US20190227082A1
(en)
|
2016-07-06 |
2019-07-25 |
Prothena Biosciences Limited |
Assay for detecting total and s129 phosphorylated alpha-synuclein
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
US20190330318A1
(en)
|
2016-07-25 |
2019-10-31 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
EP3491387A1
(en)
|
2016-07-28 |
2019-06-05 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods of treatement of cancer disease by targetting tumor associated macrophage
|
KR102554331B1
(ko)
|
2016-08-12 |
2023-07-10 |
얀센 바이오테크 인코포레이티드 |
향상된 효능적 활성을 갖는 Fc 조작된 항-TNFR 수퍼패밀리 구성원 항체 및 그의 사용 방법
|
CA3033661A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
WO2018057618A1
(en)
|
2016-09-20 |
2018-03-29 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
|
SG10201912173RA
(en)
|
2016-10-07 |
2020-02-27 |
Daiichi Sankyo Co Ltd |
Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
|
JPWO2018070390A1
(ja)
|
2016-10-12 |
2019-08-22 |
第一三共株式会社 |
抗robo4抗体と他剤を含む組成物
|
AU2017343778A1
(en)
|
2016-10-13 |
2019-05-02 |
Massachusetts Institute Of Technology |
Antibodies that bind Zika virus envelope protein and uses thereof
|
IT201600111877A1
(it)
|
2016-11-07 |
2018-05-07 |
Biouniversa Srl |
Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
|
BR112019010064A2
(pt)
|
2016-11-18 |
2019-10-01 |
Astellas Pharma Inc |
novo fragmento fab do anticorpo muc1 anti-humano
|
EP3552626A4
(en)
|
2016-12-12 |
2020-06-10 |
Daiichi Sankyo Company, Limited |
ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
|
US11180554B2
(en)
|
2016-12-13 |
2021-11-23 |
Astellas Pharma Inc. |
Anti-human CD73 antibody
|
IL267340B2
(en)
|
2016-12-15 |
2023-12-01 |
Nat Inst Biotechnology Negev Ltd |
Monoclonal antibodies against PCNA and their use
|
IL311136A
(en)
|
2016-12-22 |
2024-04-01 |
Daiichi Sankyo Co Ltd |
Anti-CD3 antibody for use in the treatment or prevention of cancer and molecules containing the antibody
|
US20180179490A1
(en)
|
2016-12-27 |
2018-06-28 |
Miltenyi Biotec Gmbh |
CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS
|
US11773182B2
(en)
|
2017-01-05 |
2023-10-03 |
The Johns Hopkins University |
Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
|
JP6679762B2
(ja)
|
2017-01-17 |
2020-04-15 |
第一三共株式会社 |
抗gpr20抗体及び抗gpr20抗体−薬物コンジュゲート
|
WO2018140510A1
(en)
|
2017-01-25 |
2018-08-02 |
Biogen Ma Inc. |
Compositions and methods for treatment of stroke and other cns disorders
|
CN110462038A
(zh)
|
2017-02-07 |
2019-11-15 |
第一三共株式会社 |
抗gprc5d抗体和包含所述抗体的分子
|
EP3363459A1
(en)
|
2017-02-17 |
2018-08-22 |
Alexander Klimka |
Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis
|
US11623953B2
(en)
|
2017-02-27 |
2023-04-11 |
Caerus Therapeutics, Inc. |
Antibody constructs and methods of treating cancer
|
BR112019015915A2
(pt)
|
2017-02-28 |
2020-04-07 |
Daiichi Sankyo Co Ltd |
método para o tratamento de câncer de pulmão de células não pequenas resistentes a egfr-tki através da administração do conjugado de anticorpo anti-her3-fármaco
|
EP4095161A1
(en)
|
2017-03-15 |
2022-11-30 |
Tsinghua University |
Novel anti-trkb antibodies
|
JOP20180021A1
(ar)
|
2017-03-16 |
2019-01-30 |
Janssen Biotech Inc |
الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
US11879014B2
(en)
|
2017-03-17 |
2024-01-23 |
Tusk Therapeutics Ltd. |
Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
|
AU2018242152B2
(en)
|
2017-03-30 |
2022-05-12 |
Ecs-Progastrin Sa |
Compositions and methods for detecting prostate cancer
|
KR102616819B1
(ko)
|
2017-03-30 |
2023-12-21 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
폐암을 치료하기 위한 조성물 및 방법
|
TWI782000B
(zh)
|
2017-03-30 |
2022-11-01 |
日商第一三共股份有限公司 |
抗gpr20抗體、其製造方法及其應用
|
US10722589B2
(en)
|
2017-04-03 |
2020-07-28 |
Covagen Ag |
FGFR3 binding molecules
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
EP3610264A1
(en)
|
2017-04-13 |
2020-02-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
WO2018209301A1
(en)
|
2017-05-11 |
2018-11-15 |
Cytodyn Inc. |
Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents
|
TW202330036A
(zh)
|
2017-05-15 |
2023-08-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之製造方法
|
PE20200294A1
(es)
|
2017-06-05 |
2020-02-05 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y metodos de uso
|
EP3634496A4
(en)
|
2017-06-06 |
2021-09-08 |
Dana-Farber Cancer Institute, Inc. |
METHOD FOR RISING AWARENESS IN CANCER CELLS AGAINST T-CELL-MEDIATED KILLING BY MODULATING MOLECULAR SIGNAL PATHS
|
WO2019005503A1
(en)
|
2017-06-29 |
2019-01-03 |
Rutgers, The State University Of New Jersey |
COMPOSITIONS AND METHODS TARGETING G12 SIGNALING FOR BRONCHODILATORY THERAPY
|
US20200115446A1
(en)
|
2017-06-30 |
2020-04-16 |
National University Corporation Hokkaido University |
Pediatric osteoporosis drug that does not cause growth disorder
|
TWI795415B
(zh)
|
2017-07-07 |
2023-03-11 |
日商安斯泰來製藥股份有限公司 |
新穎的抗人類CEACAM5抗體Fab片段
|
WO2019018744A1
(en)
|
2017-07-21 |
2019-01-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS
|
CA3071234A1
(en)
|
2017-07-27 |
2019-01-31 |
Daiichi Sankyo Company, Limited |
Anti-cd147 antibody
|
EP3658582A1
(en)
|
2017-07-28 |
2020-06-03 |
Intrepida Bio, Inc. |
Anti-bag3 antibodies as therapeutic reagent in cardiovascular diseases
|
EP3625254B1
(en)
|
2017-07-31 |
2023-12-13 |
F. Hoffmann-La Roche AG |
Three-dimensional structure-based humanization method
|
EP3444272A1
(en)
|
2017-08-17 |
2019-02-20 |
International-Drug-Development-Biotech |
Treatment of ck8 positive cancers in relation with k-ras gene status
|
SG11202001011XA
(en)
|
2017-08-23 |
2020-03-30 |
Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft |
Chimeric antigen receptor and car-t cells that bind cxcr5
|
CA3073383C
(en)
|
2017-08-23 |
2023-10-31 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate preparation and lyophilization for same
|
EP3677589A4
(en)
|
2017-08-31 |
2021-04-21 |
Daiichi Sankyo Company, Limited |
IMPROVED PROCESS FOR PREPARING ANTIBODY-ACTIVE CONJUGATE
|
CN117838880A
(zh)
|
2017-08-31 |
2024-04-09 |
第一三共株式会社 |
制备抗体-药物缀合物的新方法
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
US11628223B2
(en)
|
2017-09-29 |
2023-04-18 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines
|
WO2019069561A1
(ja)
|
2017-10-03 |
2019-04-11 |
公益財団法人東京都医学総合研究所 |
インフルエンザに対する医薬
|
US20200262917A1
(en)
|
2017-10-05 |
2020-08-20 |
Daiichi Sankyo Company, Limited |
Composition for cytotoxic t cell depletion
|
KR101966362B1
(ko)
*
|
2017-10-20 |
2019-04-05 |
주식회사 녹십자 |
항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
|
WO2019094595A2
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
WO2019108974A1
(en)
|
2017-11-30 |
2019-06-06 |
Centurion Biopharma Corporation |
Albumin-binding prodrugs of auristatin e derivatives
|
AU2018375788A1
(en)
|
2017-11-30 |
2020-07-09 |
Ladrx Corporation |
Maytansinoid-based drug delivery systems
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
TWI763956B
(zh)
|
2017-12-05 |
2022-05-11 |
盧森堡商前胃泌激素及癌症有限公司 |
治療癌症的抗前胃泌激素抗體與免疫療法之組合療法
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
US20190225689A1
(en)
|
2018-01-22 |
2019-07-25 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-pd-1 antibodies
|
TW201940881A
(zh)
|
2018-01-26 |
2019-10-16 |
瑞士商Ecs前胃泌激素公司 |
在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
|
JP7458318B2
(ja)
|
2018-02-12 |
2024-03-29 |
ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド |
癌治療のためのslamf6スプライスバリアントの調節
|
WO2019158512A1
(en)
|
2018-02-13 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prognosis and the treatment of glioblastoma
|
KR20200144541A
(ko)
|
2018-02-27 |
2020-12-29 |
이씨에스-프로가스트린 에스에이 |
면역치료요법용 생체표지자로서 프로가스트린
|
US20190292188A1
(en)
|
2018-02-27 |
2019-09-26 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
CN111836643A
(zh)
|
2018-03-05 |
2020-10-27 |
学校法人埼玉医科大学 |
用于治疗或预防异位骨化的药物组合物
|
EP3775206A1
(en)
|
2018-03-28 |
2021-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
EP3775908A1
(en)
|
2018-04-13 |
2021-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
|
SG11202009626QA
(en)
|
2018-04-20 |
2020-10-29 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
|
WO2019207066A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for the treatment of sjögren's syndrome
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
AU2019264965A1
(en)
|
2018-05-09 |
2020-11-19 |
Nectin Therapeutics Ltd. |
Antibodies specific to human Nectin4
|
US20210163957A1
(en)
|
2018-05-11 |
2021-06-03 |
Astellas Pharma Inc. |
Nucleic acid for treating mite allergy
|
TW202016311A
(zh)
|
2018-05-11 |
2020-05-01 |
日商安斯泰來製藥股份有限公司 |
用於甲殼類過敏治療之核酸
|
US20210340276A1
(en)
|
2018-05-17 |
2021-11-04 |
Astellas Pharma Inc. |
Complex having anti-human muc1 antibody fab fragment, peptide linker and/or ligand
|
CA3100731A1
(en)
|
2018-05-18 |
2019-11-21 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
SG11202011633SA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Psma binding agents and uses thereof
|
PE20210132A1
(es)
|
2018-05-24 |
2021-01-19 |
Janssen Biotech Inc |
Anticuerpos anti-cd3 y usos de estos
|
CN112703203A
(zh)
|
2018-05-24 |
2021-04-23 |
詹森生物科技公司 |
单特异性和多特异性抗-tmeff2抗体及其用途
|
CN112153989A
(zh)
|
2018-05-28 |
2020-12-29 |
第一三共株式会社 |
通过施用抗her2抗体-药物缀合物治疗her2突变的癌
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
AU2019279206A1
(en)
|
2018-05-31 |
2020-12-03 |
Daiichi Sankyo Company, Limited |
Anti-human TLR7 antibody
|
JP7398396B2
(ja)
|
2018-06-01 |
2023-12-14 |
ノバルティス アーゲー |
Bcmaに対する結合分子及びその使用
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
WO2019246110A1
(en)
|
2018-06-20 |
2019-12-26 |
Incyte Corporation |
Anti-pd-1 antibodies and uses thereof
|
US20210277118A1
(en)
|
2018-06-21 |
2021-09-09 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
AR117600A1
(es)
|
2018-06-29 |
2021-08-18 |
Incyte Corp |
Formulaciones de un inhibidor de axl / mer
|
WO2020007898A1
(en)
|
2018-07-04 |
2020-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating brain injury or neurodegenerative disease
|
CA3105721A1
(en)
|
2018-07-05 |
2020-01-09 |
Incyte Corporation |
Fused pyrazine derivatives as a2a / a2b inhibitors
|
EP3828206A4
(en)
|
2018-07-25 |
2022-04-20 |
Daiichi Sankyo Company, Limited |
METHOD OF PREPARING AN ANTIBODY DRUG CONJUGATE
|
WO2020022499A1
(ja)
|
2018-07-27 |
2020-01-30 |
国立大学法人大阪大学 |
老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物
|
EP3831853A4
(en)
|
2018-07-27 |
2022-06-01 |
Daiichi Sankyo Company, Limited |
ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT
|
TWI822822B
(zh)
|
2018-07-31 |
2023-11-21 |
日商第一三共股份有限公司 |
抗體-藥物結合物之用途
|
US20210290775A1
(en)
|
2018-08-06 |
2021-09-23 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and tubulin inhibitor
|
CN112714649B
(zh)
|
2018-09-06 |
2024-07-02 |
第一三共株式会社 |
环状二核苷酸衍生物及其抗体药物偶联物
|
CA3113207A1
(en)
|
2018-09-20 |
2020-03-26 |
Daiichi Sankyo Company, Limited |
Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate
|
WO2020059847A1
(ja)
|
2018-09-21 |
2020-03-26 |
国立大学法人 東京医科歯科大学 |
ヒトhmgb1に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
|
BR112021005655A2
(pt)
|
2018-09-27 |
2021-06-29 |
Pierre Fabre Medicament |
ligantes à base de sulfomaleimida e conjugados correspondentes
|
US20220048966A1
(en)
|
2018-09-28 |
2022-02-17 |
Pierre Fabre Medicament |
New immunocytokines for the treatment of cancer
|
WO2020075746A1
(ja)
|
2018-10-10 |
2020-04-16 |
アステラス製薬株式会社 |
標識部-抗ヒト抗体Fabフラグメント複合体を含む医薬組成物
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
CN112955462B
(zh)
|
2018-10-18 |
2024-05-07 |
国家医疗保健研究所 |
用于治疗实体瘤的βIG-H3拮抗剂和免疫检查点抑制剂的组合
|
CN112930195B
(zh)
|
2018-10-31 |
2024-03-19 |
安斯泰来制药株式会社 |
抗人Fn14抗体
|
WO2020099235A1
(en)
|
2018-11-12 |
2020-05-22 |
Mediapharma S.R.L. |
Bispecific antibodies directed against human 90k and either endosialin or her3
|
JP7401456B2
(ja)
|
2018-11-14 |
2023-12-19 |
第一三共株式会社 |
抗cdh6抗体-ピロロベンゾジアゼピン誘導体コンジュゲート
|
CN113271942A
(zh)
|
2018-12-11 |
2021-08-17 |
第一三共株式会社 |
抗体-药物缀合物与parp抑制剂的组合
|
JPWO2020130125A1
(ja)
|
2018-12-21 |
2021-11-04 |
第一三共株式会社 |
抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
|
KR20210106531A
(ko)
|
2018-12-21 |
2021-08-30 |
에임 이뮤노테크 인코포레이티드 |
암 치료를 위한 조성물 및 방법
|
AU2020205851A1
(en)
|
2019-01-07 |
2021-08-12 |
Astellas Pharma Inc. |
Conjugate comprising ligand, spacer, peptide linker, and biomolecule
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
KR20210117277A
(ko)
|
2019-01-13 |
2021-09-28 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
인간 넥틴-2에 특이적인 항체
|
EP3917515A1
(en)
|
2019-01-29 |
2021-12-08 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Treating the causative agent in adhesiogenesis
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
US11028176B2
(en)
|
2019-02-13 |
2021-06-08 |
The Brigham And Women's Hospital, Inc. |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
WO2020178193A1
(en)
|
2019-03-01 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of sarcoidosis
|
EP3942026A1
(en)
|
2019-03-22 |
2022-01-26 |
Université de Paris |
New inhibitors of lrrk2/pp1 interaction
|
ES2967879T3
(es)
|
2019-03-25 |
2024-05-06 |
Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft |
Mejora de la actividad de los linfocitos T citolíticos mediante la inhibición de EBAG9
|
CN113631229A
(zh)
|
2019-03-25 |
2021-11-09 |
第一三共株式会社 |
抗体-吡咯并苯并二氮杂卓衍生物偶联物
|
SG11202109860VA
(en)
|
2019-03-25 |
2021-10-28 |
Daiichi Sankyo Co Ltd |
Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
|
EP3949988A4
(en)
|
2019-03-27 |
2022-11-16 |
Daiichi Sankyo Company, Limited |
COMBINATION OF AN ANTIBODY-DERIVATIVE CONJUGATE OF PYRROLOBENZODIAZEPINE AND A PARP INHIBITOR
|
CN113660954A
(zh)
|
2019-04-01 |
2021-11-16 |
凯奥目生物科学株式会社 |
癌症治疗用药物
|
AU2020253449A1
(en)
|
2019-04-02 |
2021-11-18 |
Kenjockety Biotechnology, Inc. |
Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
|
CN113747944A
(zh)
|
2019-04-19 |
2021-12-03 |
詹森生物科技公司 |
用抗psma/cd3抗体治疗前列腺癌的方法
|
CN114007642A
(zh)
|
2019-04-30 |
2022-02-01 |
森迪生物科学公司 |
嵌合受体及其使用方法
|
EP3962529A4
(en)
|
2019-04-30 |
2023-11-01 |
Dana-Farber Cancer Institute, Inc. |
METHOD FOR CANCER TREATMENT USING ANTI-CX3CR1 AND IMMUNE CHECKPOINT BLOCKING REAGENTS COMBINATIONS
|
US20220259561A1
(en)
|
2019-05-14 |
2022-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
|
BR112021023901A2
(pt)
|
2019-05-29 |
2022-01-18 |
Daiichi Sankyo Co Ltd |
Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer
|
CN114286828A
(zh)
|
2019-06-24 |
2022-04-05 |
诺华股份有限公司 |
针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
|
WO2021020282A1
(ja)
|
2019-07-26 |
2021-02-04 |
学校法人埼玉医科大学 |
Alk2/acvr1の細胞外領域を認識する抗体
|
KR20220040483A
(ko)
|
2019-07-26 |
2022-03-30 |
얀센 바이오테크 인코포레이티드 |
칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
|
WO2021019706A1
(ja)
|
2019-07-31 |
2021-02-04 |
国立大学法人信州大学 |
Car発現免疫細胞を含む細胞集団の製造方法
|
AU2020319875A1
(en)
|
2019-08-01 |
2022-02-17 |
Incyte Corporation |
A dosing regimen for an IDO inhibitor
|
CN114502594A
(zh)
|
2019-08-02 |
2022-05-13 |
西托戴恩股份有限公司 |
牵涉施用抗-ccr5受体试剂的用于治疗或预防癌症的方法
|
JP7284256B2
(ja)
|
2019-08-12 |
2023-05-30 |
ビオンド バイオロジクス リミテッド |
Ilt2に対する抗体およびその使用
|
EP3792632A1
(en)
|
2019-09-16 |
2021-03-17 |
Vito NV |
Immunotherapy markers
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
US20220290151A1
(en)
|
2019-09-27 |
2022-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of müllerian inhibiting substance inhibitors for treating cancer
|
CN114746119A
(zh)
|
2019-09-27 |
2022-07-12 |
詹森生物科技公司 |
抗-ceacam抗体及其用途
|
CN114630679A
(zh)
|
2019-10-25 |
2022-06-14 |
第一三共株式会社 |
抗garp抗体和免疫调节剂的组合
|
KR20220113386A
(ko)
|
2019-11-15 |
2022-08-12 |
플라이언트 테라퓨틱스, 인크. |
인테그린의 활성화를 위한 조성물 및 방법
|
WO2021099906A1
(en)
|
2019-11-18 |
2021-05-27 |
Janssen Biotech, Inc. |
Vaccines based on mutant calr and jak2 and their uses
|
CN112500483B
(zh)
*
|
2019-12-10 |
2022-11-29 |
西西欧艾(杭州)生物医药有限责任公司 |
抗血小板膜糖蛋白ib alpha人源化抗体及其应用
|
CA3164996A1
(en)
|
2019-12-20 |
2021-06-14 |
Novarock Biotherapeutics, Ltd. |
Anti-interleukin-23 p19 antibodies and methods of use thereof
|
CA3166549A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
|
WO2021140173A1
(en)
|
2020-01-10 |
2021-07-15 |
Biouniversa S.R.L. |
Methods and uses for treating fibrotic solid tumors with bags inhibitors
|
US20230070181A1
(en)
|
2020-02-05 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of cancer disease by targeting an epigenetic factor
|
TW202140012A
(zh)
|
2020-02-12 |
2021-11-01 |
比利時商健生藥品公司 |
用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
JP2023519153A
(ja)
|
2020-03-03 |
2023-05-10 |
アクティブ バイオテック エイビー |
組合せ療法における使用のためのタスキニモドまたはその薬学的に許容される塩
|
CN115209921A
(zh)
|
2020-03-06 |
2022-10-18 |
第一三共株式会社 |
包含新型环状二核苷酸衍生物的抗体药物偶联物
|
WO2021178779A1
(en)
|
2020-03-06 |
2021-09-10 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
BR112022017924A2
(pt)
|
2020-03-10 |
2022-12-20 |
Massachusetts Inst Technology |
Composições e métodos para imunoterapia de câncer npm1c-positivo
|
EP4117715A1
(en)
|
2020-03-13 |
2023-01-18 |
Janssen Biotech, Inc. |
Materials and methods for binding siglec-3/cd33
|
JPWO2021200131A1
(ja)
|
2020-03-30 |
2021-10-07 |
|
|
US11045546B1
(en)
|
2020-03-30 |
2021-06-29 |
Cytodyn Inc. |
Methods of treating coronavirus infection
|
EP3889183A1
(en)
|
2020-04-01 |
2021-10-06 |
Pierre Fabre Medicament |
A protein complex comprising an immunocytokine
|
BR112022020232A2
(pt)
|
2020-04-06 |
2022-12-13 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Anticorpos contra nkp46 e construtos dos mesmos para o tratamento de cânceres e infecções
|
TW202144429A
(zh)
|
2020-05-14 |
2021-12-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗cd25抗體、其抗原結合片段及其醫藥用途
|
US20230192879A1
(en)
|
2020-05-19 |
2023-06-22 |
Institut Curie |
Methods for the diagnosis and treatment of cytokine release syndrome
|
EP4157459A1
(en)
|
2020-05-27 |
2023-04-05 |
Janssen Biotech, Inc. |
Proteins comprising cd3 antigen binding domains and uses thereof
|
CN116133684A
(zh)
|
2020-05-27 |
2023-05-16 |
阿里亚利斯治疗公司 |
抗人nr1抗体衍生物
|
AU2021283080A1
(en)
|
2020-06-04 |
2022-12-15 |
Kenjockety Biotechnology, Inc. |
ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
|
WO2021260582A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and aurora b inhibitor
|
JP2023542065A
(ja)
|
2020-06-24 |
2023-10-05 |
アストラゼネカ ユーケー リミテッド |
抗体-薬物複合物及びcdk9阻害剤の組み合わせ
|
WO2021260583A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and dna-pk inhibitor
|
CN116194109A
(zh)
|
2020-06-24 |
2023-05-30 |
阿斯利康(英国)有限公司 |
抗体-药物缀合物和atm抑制剂的组合
|
JP2023542066A
(ja)
|
2020-06-24 |
2023-10-05 |
アストラゼネカ ユーケー リミテッド |
抗体-薬物コンジュゲートとatr阻害剤との組み合わせ
|
EP4171527A1
(en)
|
2020-06-25 |
2023-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment and diagnostic of pathological conditions associated with intense stress
|
TW202216212A
(zh)
|
2020-07-17 |
2022-05-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之製造方法
|
IL300030A
(en)
|
2020-07-20 |
2023-03-01 |
Daiichi Sankyo Co Ltd |
Combination of an anti-2HER drug-antibody conjugate with a dimerization suppressor
|
EP4188439A2
(en)
|
2020-07-29 |
2023-06-07 |
Janssen Biotech, Inc. |
Proteins comprising hla-g antigen binding domains and their uses
|
RU2764216C1
(ru)
*
|
2020-08-10 |
2022-01-14 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" |
Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения
|
JP2023537396A
(ja)
|
2020-08-12 |
2023-08-31 |
ビオンド バイオロジクス リミテッド |
Ilt2に対する抗体およびその使用
|
EP4199959A1
(en)
|
2020-08-24 |
2023-06-28 |
Charité - Universitätsmedizin Berlin |
A chimeric antigen receptor construct encoding a checkpoint inhibitory molecule and an immune stimulatory cytokine and car-expressing cells recognizing cd44v6
|
JP2023540023A
(ja)
|
2020-08-24 |
2023-09-21 |
シャリテ-ウニベルジテーツメディツィン ベルリン |
Ceaを認識するキメラ抗原受容体(car)発現細胞
|
EP4208259A2
(en)
|
2020-09-04 |
2023-07-12 |
NovaRock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
WO2022049273A1
(en)
|
2020-09-07 |
2022-03-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of inflammatory bowel diseases
|
KR20230066094A
(ko)
|
2020-09-12 |
2023-05-12 |
아스트라제네카 유케이 리미티드 |
항-her2 항체-약물 접합체 치료법을 위한 채점 방법
|
TW202228692A
(zh)
|
2020-10-05 |
2022-08-01 |
日商凱依歐姆 生物科學股份有限公司 |
癌症治療用醫藥
|
IL301921A
(en)
|
2020-10-09 |
2023-06-01 |
Daiichi Sankyo Co Ltd |
Combining an antibody-drug conjugate and a selective 1PARP inhibitor
|
EP4228693A1
(en)
|
2020-10-13 |
2023-08-23 |
Janssen Biotech, Inc. |
Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
|
EP4232064A1
(en)
|
2020-10-21 |
2023-08-30 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
C-terminal sparc fragments for treating cancer
|
TW202233672A
(zh)
|
2020-10-22 |
2022-09-01 |
美商健生生物科技公司 |
包括類δ配體3(DLL3)抗原結合區之蛋白質及其用途
|
WO2022097090A1
(en)
|
2020-11-05 |
2022-05-12 |
Novartis Ag |
Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
|
EP4240874A1
(en)
|
2020-11-06 |
2023-09-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for diagnosis and treating polycystic ovary syndrome (pcos)
|
KR20230106645A
(ko)
|
2020-11-11 |
2023-07-13 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트와 항 SIRPα 항체의 조합
|
JPWO2022102695A1
(ja)
|
2020-11-12 |
2022-05-19 |
|
|
IL302544A
(en)
|
2020-11-16 |
2023-07-01 |
Astellas Pharma Inc |
Anti-TSPAN8-anti-CD3 bispecific antibody and anti-TSPAN8 antibody
|
US20240003879A1
(en)
|
2020-11-27 |
2024-01-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring of toxic epidermal necrolysis
|
WO2022115120A1
(en)
|
2020-11-30 |
2022-06-02 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
US20220241411A1
(en)
|
2020-11-30 |
2022-08-04 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
WO2022124247A1
(ja)
|
2020-12-09 |
2022-06-16 |
国立大学法人 東京医科歯科大学 |
前頭側頭葉変性症の予防又は治療剤
|
TW202241441A
(zh)
|
2020-12-29 |
2022-11-01 |
美商英塞特公司 |
包含a2a/a2b抑制劑、pd-1/pd-l1抑制劑及抗cd73抗體之組合療法
|
EP4277665A1
(en)
|
2021-01-13 |
2023-11-22 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3 antibody-drug conjugate
|
KR20230146521A
(ko)
|
2021-01-13 |
2023-10-19 |
메모리얼 슬로안 케터링 캔서 센터 |
항체-피롤로벤조디아제핀 유도체 접합체
|
WO2022153212A1
(en)
|
2021-01-13 |
2022-07-21 |
Axon Neuroscience Se |
Antibodies neutralizing sars-cov-2
|
KR20230137393A
(ko)
|
2021-01-28 |
2023-10-04 |
얀센 바이오테크 인코포레이티드 |
Psma 결합 단백질 및 이의 용도
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體-免疫賦活化劑共軛物之新穎製造方法
|
EP4291580A1
(en)
|
2021-02-11 |
2023-12-20 |
Nectin Therapeutics Ltd. |
Antibodies against cd112r and uses thereof
|
TW202246319A
(zh)
|
2021-02-12 |
2022-12-01 |
德商百靈佳殷格翰國際股份有限公司 |
補體c3抗原結合蛋白
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
MX2023010238A
(es)
|
2021-03-02 |
2023-12-05 |
Dana Farber Cancer Inst Inc |
Métodos para tratar trastornos de glóbulos rojos.
|
WO2022189632A1
(en)
|
2021-03-12 |
2022-09-15 |
Fibrosys S.R.L. |
Monoclonal antibodies for the treatment of viral infections
|
JPWO2022191313A1
(ja)
|
2021-03-12 |
2022-09-15 |
|
|
AU2022244453A1
(en)
|
2021-03-24 |
2023-11-09 |
Janssen Biotech, Inc. |
Antibody targeting cd22 and cd79b
|
EP4314059A1
(en)
|
2021-03-26 |
2024-02-07 |
Janssen Biotech, Inc. |
Humanized antibodies against paired helical filament tau and uses thereof
|
WO2022218998A1
(en)
|
2021-04-13 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating hepatitis b and d virus infection
|
CR20230523A
(es)
|
2021-04-14 |
2024-01-23 |
Villaris Therapeutics Inc |
Anticuerpos anti-cd122 y usos de estos
|
KR20230171465A
(ko)
|
2021-04-22 |
2023-12-20 |
아스텔라스세이야쿠 가부시키가이샤 |
항cldn4-항cd137 이중특이성 항체
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
CN113361141B
(zh)
*
|
2021-07-11 |
2022-02-18 |
西南石油大学 |
一种dna图谱算法的改进试验方法
|
AU2022333321A1
(en)
|
2021-08-27 |
2024-04-11 |
Janssen Biotech, Inc. |
Anti-psma antibodies and uses thereof
|
AU2022347380A1
(en)
|
2021-09-15 |
2024-04-11 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
JPWO2023068226A1
(ja)
|
2021-10-18 |
2023-04-27 |
|
|
WO2023073084A1
(en)
|
2021-10-27 |
2023-05-04 |
Imcheck Therapeutics |
Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
|
EP4177266A1
(en)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralizing anti-sars-cov-2 human antibodies
|
CA3238116A1
(en)
|
2021-11-18 |
2023-05-25 |
Matthew Simon SUNG |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
WO2023089032A1
(en)
|
2021-11-19 |
2023-05-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
TW202334231A
(zh)
|
2021-12-22 |
2023-09-01 |
德商莫菲西斯公司 |
抗cd19抗體療法的治療範例
|
TW202333800A
(zh)
|
2021-12-28 |
2023-09-01 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物及rasg12c抑制劑之組合
|
TW202339805A
(zh)
|
2021-12-28 |
2023-10-16 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物及atr抑制劑之組合
|
WO2023152581A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
Method of treating cancer with psmaxcd3 antibody
|
WO2023166081A1
(en)
|
2022-03-02 |
2023-09-07 |
Heidelberg Immunotherapeutics Gmbh |
Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
|
WO2023175614A1
(en)
|
2022-03-15 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
|
WO2023175483A1
(en)
|
2022-03-16 |
2023-09-21 |
Astrazeneca Uk Limited |
A scoring method for an anti-trop2 antibody‑drug conjugate therapy
|
WO2023209591A1
(en)
|
2022-04-27 |
2023-11-02 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
|
TW202400650A
(zh)
|
2022-05-11 |
2024-01-01 |
日商第一三共股份有限公司 |
抗體與cd47抑制劑之組合
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
WO2024013723A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
TW202412859A
(zh)
|
2022-07-28 |
2024-04-01 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物及雙特異性檢查點抑制劑之組合
|
WO2024072893A1
(en)
|
2022-09-28 |
2024-04-04 |
Incyte Corporation |
Anti-pd-1/lag-3 bispecific antibodies and uses thereof
|
WO2024074498A1
(en)
|
2022-10-04 |
2024-04-11 |
Imcheck Therapeutics |
Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
|
WO2024116094A1
(en)
|
2022-11-30 |
2024-06-06 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugates and dnmt inhibitors
|
WO2024121380A1
(en)
|
2022-12-08 |
2024-06-13 |
Pierre Fabre Medicament |
Vaccinal composition and adjuvant
|
WO2024127366A1
(en)
|
2022-12-16 |
2024-06-20 |
Pheon Therapeutics Ltd |
Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof
|